Podcasts about NK

Statistics show that 1 in 3 people will receive a cancer diagnosis in their lifetime...     But the good news is that your body holds a powerful built-in defense: natural killer (NK) and T cells that help identify and destroy abnormal cells before they can spread.     On today's show, I'll share why these immune cells are your first line of defense against cancer and how simple diet, lifestyle, and supplement strategies can help boost their activity naturally.     So join me on today's Cabral Concept 3401 to learn how to activate your natural killer, anti-cancer cells.     Enjoy the show and let me know your thoughts!   - - - For Everything Mentioned In Today's Show: StephenCabral.com/3401 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!  

In this episode of The Worst Girl Gang Ever, hosts Bex Gunn and Laura Buckingham sit down with Kerry Etheridge, who bravely opens up about her devastating experiences with baby loss, trauma during medical termination, and recurrent miscarriage. Kerry shares the raw details of her first-trimester scan that turned into heartbreak, being forced to give birth to her baby on a labour ward, and the lifelong trauma of being handed her baby in a bedpan. She discusses the lack of support, nervous system dysregulation, and the emotional aftermath of being expected to return to her client-facing job as if nothing had happened. But Kerry's story doesn't stop at suffering. She takes us through her journey of recurrent miscarriages, battling the system, exploring immunology, and eventually retraining to become a fertility nutritionist, supporting other women through their own paths to conception.

Zákaz krížového vlastníctva medzi zdravotnými poisťovňami a nemocnicami, ale aj zrušenie odvodov a ich prerod na dane, čo by vyšachovalo súkromné poisťovne z biznisu s našimi odvodmi. I to sú témy, ktoré by mohli zásadne posunúť naše zlyhávajúce zdravotníctvo. Tvrdí to poslanec PS Oskar Dvořák. Nie je však politická scéna až príliš prepletená so záujmami tzv. Pentagelu? Zdravotníctvo nebolo nikdy prioritou tohto štátu. Priznáva to dnes otvorene už aj premiér Fico, keď zdravotníctvo ako premiérsku tému opakovane odmieta, tvrdí v rozhovore pre Aktuality poslanec PS Oskar Dvořák.Privatizáciou zdravotných odvodov sme si v zdravotníctve vyrobili peklo, hovorí na margo zajacovej reformy, ktorou sa umožnilo vytváranie zisku z verejných zdrojov, bývalá šéfka Úradu pre dohľad nad zdravotnou starostlivosťou Renáta Bláhová. Dnes, po vyše 20tich rokov vidíme výsledky:Štát na verejný záujem v zdravotníctve rezignoval, pacienti ho nezaujímajú a ministerstvo zdravotníctva ovládli lobisti, hovorí v až šokujúco otvorenej kritike pre Ráno Nahlas šéf Najvyššieho kontrolného úradu Ľubomír Andrassy.Napriek tomu, že zdravotníctvo patrí medzi kľúčové oblasti, ktoré nás ako občanov trápia a napriek tomu, že do zdravotníctva neliavame každoročne čoraz viac miliárd, efektivita, kvalita i dostupnosť zdravotných služieb sa pre pacientov nelepšia, ba práve naopak. Navyše, systém, ktorý nás čoraz častejšie núti zháňať peniaze na inovatívne lieky či modernú liečbu po všakovakých zbierkach, stále umožňuje súkrormných finančným žralokom generovať z našich verejných zdrojov ich súkromné zisky.Je toto naozaj v poriadku alebo už dozrel čas na skutočne zásadnú zmenu slovenského zdravotníctva? Bolo by krokom vpred zrušenie zdravotných odvodov či zákaz krížového vlastníctva? Naozaj podľahol štát - i politici naprieč stranami, lobistom z finančných skupín a ako vlastne osedlať a zregulovať záujmy predátorského kapitálu v tejto tak citlivej sfére?"Máme už analýzy Útvaru hodnoty za peniaze, ako i Úradu pre Dohľad nad zdravotnou starostlivosťou no a teraz to hovorí už aj NKÚ, že skutočne sú tu niektorí hráči, ktorí zo zdravotníckeho systému dokážu vyťažiť viac. No a kto má dnes prísť a riešiť to? Má prísť štát - ako regulátor, a využiť napríklad programovú vyhlášku, má si pohnúť so zavádzaním DRG a má opraviť všetky tieto nedostatky. Ak doteraz nekonal, ja by som to nazval spolupáchateľstvo. Neviem či vedome alebo nevedome, ale je to spolupáchateľstvo," tvrdí poslanec Progresívneho Slovenska Oskar Dvořák.Ráno Nahlas s expertom na zdravotníctvo a poslancom Progresívneho Slovenska Oskarom Dvořákom. Pekný deň a pokoj v duši praje Braňo Dobšinký. P.S.Spomínanú liekovú vyhlášku minister zdravotníctva napokon nepodpísal. Kamil Šaško vyhlásil, že vyhláška nevstúpi do platnosti, kým - jeho slovami, nedosiahne "odbornú zhodu."

Penzionová výzva je kolosálny podvod, Pôdohospodárska platobná agnentúra je nefunkčná, netransparentná a skorumpovaná organizácia, ktorú nie je možné nijako sfunkčniť. Jediným riešením je ju rozpustiť a založiť úplne nanovo, hovorí v Ráno Nahlas Zuzana Šubová, ktorá pôsobila v protikorupčnej zložke PPA."Peniaze, ktoré mali ísť na podporu cestovného ruchu skončili v súkromných haciendách. Našli sme ďalšie dotácie. Nitky vedú k obžalovanému oligarchovi Bödörovi, ktorého si premiér pozýva na úrad vlády." To je úryvok zo statusu Nadácie Zastavme korupciu na margo takzvanej penziónovej kauzy.O čo ide?Penzióny, ktoré fakticky nie sú žiadnymi penziónmi, takzvaná penziónová výzva. V nej, počas vlády Roberta Fica, agentúra PPA finančne podporila výstavbu ubytovania pre turistov. To sa však podľa kritikov i médií, čoraz viac ukazuje ako kolosálny podvod. Deje sa to pritom v presne tej istej agentúre, ktorá je spojená i so známou kauzou Dobytkár - kde išlo o netransparentné rozdeľovanie agrodotácií - a v ktorej priamo sudca hovoril o "megastroji korupcie a prania špinavých peňazí."Navyše, PPA je predmetom opakovaných hĺbkových kontrol Najvyššieho kontrolného úradu, ktorý však i po rokoch kontrol nie je schopný - a ani ochotný, PPAčke udeliť takzvanú okrúhlu pečiatku spoľahlivosti."Existencia korupčných rizík a netransparentnosť procesov sú na Pôdohospodárskej platobnej agentúre naďalej významnou hrozbou a jej protifraudový program nemožno ani po poslednej kontrole Najvyššieho kontrolného úradu považovať za dostatočne účinný," tvrdí NKÚ.Ako je to vôbec možné, že sa v agentúre hospodáriacej s mnohomiliónovými verejnými zdrojmi už doslova celé roky nedarí urobiť poriadok a ako to, že kauzy spojené s PPAčkou evidentne prerástli cez hlavu viacerým politickým garnitúram - od SMERu až po matovičovo OĽANO? Koľko miliónov sme už takto vyhodili do vzduchu a pochovali v prachu podozrení z korupcie a klientelizmu, kto mocný v pozadí to všetko kryje no a najmä: Čo ďalej s Poľnohospodárskou platobnou agentúrou?Ráno Nahlas s bývalou šéfkou protikorupčnej sekcie na Pôdohospodárskej platobnej agentúre a dnes predsedníčkou Pirátskej strany Zuzanou Šubovou. Pekný deň a pokoj v duši praje Braňo Dobšinský.

20. mai 2025 I dag er vi så heldige å ha med oss CEO Namir Hassan i Zelluna. Det blir en lang og hyggelig prat om bakgrunnen for sammenslåingen av Zelluna Immunotherapy og Ultimovacs, hva som gjør teknologien til Zelluna unik, den enestående patentsituasjonen til selskapet, hva som skjer i celleterapi-feltet internasjonalt - og ikke minst om det veldig spennende året som kommer, der Zelluna for aller første gang skal inn i klinikk. Dette er da den tredje podkasten på rad vi har om celleterapi, så om det var en del begreper du ikke forsto, så lytt gjerne til de to foregående podkastene med henholdsvis Sigrid Bratlie som omhandler celleterapi generelt og Karl-Johan Malmberg om hans forskning på NK-celler, som han får Kong Olav Vs kreftforskningspris for av Kreftforeningen i år.

Kontrolóri NKÚ prišli s kritickými zisteniami. Slovenské zdravotníctvo je v zajatí lobistických skupín, nemocnice sú financované neférovo a na všetko doplácajú pacienti.Ako je to možné, ak do zdravotníctva tečie ročne takmer desať miliárd eur? Kde sa tie peniaze strácajú, ak musia ľudia platiť aj za objednanie k lekárovi a mesiace čakať na termín do ambulancie či na svoju operáciu? Prečo sú veľké štátne nemocnice, ktoré riešia najťažších pacientov v miliardových dlhoch, no súkromným sa darí?Slovensko je za hranou priepasti, do ktorej začíname padať. Chýbajú nám priority, do ktorých chceme investovať naše spoločné peniaze. A šéf najvyššieho kontrolného úradu hovorí, že sa musí nanovo nakresliť fungovanie štátu.Ktoré rozhodnutia politikov to spôsobili? Máme na drahé trináste dôchodky či plošnú energopomoc? Čo znamená, že sa ciele vlády dostať deficit pod tri percentá posúva až za parlamentné voľby a ako by sa malo zmeniť financovanie politických strán? Prečo kontrolóri hovoria, že štát nemá víziu a čo to znamená pre ľudí, ich bežný život, zdravie a peňaženky?Braňo Závodský sa rozprával s predsedom Najvyššieho kontrolného úradu SR Ľubomírom Andrassym.

U nás je to v zdravotníctve celé naopak. Primárnym cieľom je dosiahnuť zisk a smerovať peniaze tam, kde to chcú silní finanční hráči, tvrdí bývalá šéfka Úradu pre dohľad nad zdravotnou starostlivosťou Renáta Bláhová. Podľa nej je systém zle nastavený pretože ho poháňa predátorský kapitál. Ako to teda zásadne zmeniť?Zdravie je dnes na Slovensku predmetom obchodovania a kšeftovania medzi veľmi úzkymi ekonomickými záujmovými skupinami, povedal nedávno pre podcast Ráno Nahlas predseda Najvyššieho kontrolného úradu Ľubomír Andrassy. Na základe opakovaných hĺbkových kontrol tvrdí, že rezort zdravotníctva neobhajuje verejný záujem a ani pacienta, ale namiesto toho je ovládané lobistickými záujmami. Do takto deravého systému je preto nalievanie ďalších miliárd úplne zbytočné pretože pre pacienta by sa nič k lepšiemu nezmenilo.Zdravotníctvo - ktoré pritom patrí medzi kľíučové problémy, ktoré trápia občanov Slovenska, sa tak stalo doslova čiernou dierou na peniaze. Hoci do neho každoročne nalievame čoraz viac a viac miliárd, starostlivosť o pacientov sa fakticky vôbec nezlepšuje. Systém je teda nielen evidentne neefektívny a deravý, ale podľa niektorých odborníkov aj zásadne a systémovo zle nastavený. Nadôvažok, kľúčovým hráčom sa stali silné finančné skupiny takzvaného "Pentagelu", teda Penty a Agelu.Medzi kritikov takto nastaveného zdravotníctva, do ktorého sme vpustili súkromný a dravý kapitál - bez dostatočných regulácií i adekvátnej sily štátu obhajovať pacientov, patrí aj bývalá šéfka Úradu pre dohľad nad zdravotnou starostlivosťou (ÚDZS)Privatizáciou sme si v zdravotníctve vyrobili peklo. To nie je žiadny voľný trh a ani ním nemôže byť. Máme tu niečo, čo smeruje k modelu v USA. Vo verejnom zdravotnom poistení sa u nás aktuálne odhadom vyberie cca 10 miliárd a súťaž nie je žiadna. Nefunguje to, hovorí Renáta Bláhová. V čom teda slovenské zdravotníctvo systémovo nefunguje a mala až šokujúco otvorená kritika šéfa NKÚ pravdu? Dokáže sa ešte štát - reprezentovaný predovšetkým ministerstvom zdravotníctva, tomuto dravému súkromnému kapitálu adekvátne čeliť a obhajovať verejný záujem a záujmy nás, pacientov? No a ak to celé nefunguje, ako to zmeniť k lepšiemu?Ráno Nahlas, opäť o zdravotníctve, dnes s bývalou šéfkou Úradu pre dohľad nad zdravotnou starostlivosťou a daňovou poradkyňou Renátou Bláhovou. Reč však bude aj o transakčnej dani, vládnej konsolidácií a možnom zdanení superbohatých. Pekný deň a pokoj v duši praje Braňo Dobšinský.

U nás je to v zdravotníctve celé naopak. Primárnym cieľom je dosiahnuť zisk a smerovať peniaze tam, kde to chcú silní finanční hráči, tvrdí bývalá šéfka Úradu pre dohľad nad zdravotnou starostlivosťou Renáta Bláhová. Podľa nej je systém zle nastavený pretože ho poháňa predátorský kapitál. Ako to teda zásadne zmeniť?Zdravie je dnes na Slovensku predmetom obchodovania a kšeftovania medzi veľmi úzkymi ekonomickými záujmovými skupinami, povedal nedávno pre podcast Ráno Nahlas predseda Najvyššieho kontrolného úradu Ľubomír Andrassy. Na základe opakovaných hĺbkových kontrol tvrdí, že rezort zdravotníctva neobhajuje verejný záujem a ani pacienta, ale namiesto toho je ovládané lobistickými záujmami. Do takto deravého systému je preto nalievanie ďalších miliárd úplne zbytočné pretože pre pacienta by sa nič k lepšiemu nezmenilo.Zdravotníctvo - ktoré pritom patrí medzi kľíučové problémy, ktoré trápia občanov Slovenska, sa tak stalo doslova čiernou dierou na peniaze. Hoci do neho každoročne nalievame čoraz viac a viac miliárd, starostlivosť o pacientov sa fakticky vôbec nezlepšuje. Systém je teda nielen evidentne neefektívny a deravý, ale podľa niektorých odborníkov aj zásadne a systémovo zle nastavený. Nadôvažok, kľúčovým hráčom sa stali silné finančné skupiny takzvaného "Pentagelu", teda Penty a Agelu.Medzi kritikov takto nastaveného zdravotníctva, do ktorého sme vpustili súkromný a dravý kapitál - bez dostatočných regulácií i adekvátnej sily štátu obhajovať pacientov, patrí aj bývalá šéfka Úradu pre dohľad nad zdravotnou starostlivosťou (ÚDZS)Privatizáciou sme si v zdravotníctve vyrobili peklo. To nie je žiadny voľný trh a ani ním nemôže byť. Máme tu niečo, čo smeruje k modelu v USA. Vo verejnom zdravotnom poistení sa u nás aktuálne odhadom vyberie cca 10 miliárd a súťaž nie je žiadna. Nefunguje to, hovorí Renáta Bláhová. V čom teda slovenské zdravotníctvo systémovo nefunguje a mala až šokujúco otvorená kritika šéfa NKÚ pravdu? Dokáže sa ešte štát - reprezentovaný predovšetkým ministerstvom zdravotníctva, tomuto dravému súkromnému kapitálu adekvátne čeliť a obhajovať verejný záujem a záujmy nás, pacientov? No a ak to celé nefunguje, ako to zmeniť k lepšiemu?Ráno Nahlas, opäť o zdravotníctve, dnes s bývalou šéfkou Úradu pre dohľad nad zdravotnou starostlivosťou a daňovou poradkyňou Renátou Bláhovou. Reč však bude aj o transakčnej dani, vládnej konsolidácií a zdanení superbohatých. Pekný deň a pokoj v duši praje Braňo Dobšinský.

14. mai 2025 I dag er vi så heldige å ha med oss forsker Karl-Johan Malmberg i podkasten vår. Kalle, som alle kaller ham, er en pionér innen forskning på naturlige drepeceller, NK-celler, og får i år Kong Olav Vs Kreftforskningspris av Kreftforeningen for arbeidet sitt. Vi snakker om bakgrunnen hans som hematolog, hvordan han som svensk, endte opp i Norge, NK-celler og når et eventuelt behandlingsgjennombrudd kan komme, ACT-senteret og samlokaliseringen med Thermo Fisher Scientific og mye, mye mer.

Čo všetko je schopný urobiť premiér tejto krajiny aby zakryl svoju neschopnosť riešiť reálne problémy Slovenska? Premiérskou témou je kvalita života na Slovensku a od toho Fico neustále uteká, hovorí bývalá premiérka Iveta Radičová. Podľa nej sa premiér Fico dnes už ani netají snahou zmeniť režim na Slovensku, vládnuť krajine však zjavne nevie. Reč bude aj o zásadnej zmene chorého zdravotníctva.Pri príležitosti osláv konca Druhej svetovej vojny navštívil slovenský premiér Moskvu a tam rokoval priamo s Vladimírom Putinom, ktorý dnes vedie vojnu na Ukrajine. Opozícia v tom má jasno a označila to za akt vlastizrady a kolaborácie s nepriateľskou mocnosťou. Medzitým ako sa slovenský premiér klaňal vládcovi Kremľa, sa však štát, ktorý vedie - či by ho aspoň viesť mal, rozpadá doslova v priamom prenose.Stav verejných financií sa napriek opakovanej konsolidácií, ktorá nám zvýšila dane a zhoršila služby štátu, príliš nezlepšil no a to nás čaká ešte ďalšie uťahovanie opaskov. Zatialčo vláda siahla na daňové bonusy na deti či šikanuje podnikateľov bizarnou transakčnou daňou, sama sa ukromniť odmieta. Ministrom rapídne narástli platy, šéf rezortu vnútra objednal pre policajtov kávové uniformy a počítače za tritisíc no a pod rukami PPA nám tu rozkvitli penziony - nepenzióny.Namiesto riešenia reálnych problémov sa ale vládna koalícia neustále zaoberá sama sebou, utočí na média či mimovládny sektor no a dokonca vedie ľúty boj za práva extrémistu Bombica či konšpirátora Kotlára..Asi najlepšie úpadok štátu definoval šéf NKÚ, ktorý v rozhovore pre Aktuality povedal, že ministerstvo zdravotníctva ovládli lobisti a štát v oblasti zdravia na verejný záujem jednoducho rezignoval. Kam teda smeruje Slovensko pod touto vládou? Podari sa Robertovi Ficovi uniesť krajinu z Európy a dokedy sa vôbec dá tento Potemkin - vydávaný za štát, ešte predstierať a imitovať modernú a funkčnú demokraciu? Naozaj práve toto voliči chcú a stačí im to? No a kde je silná, jednotná a najmä zmysluplná alternatíva politickej opozície? Témy pre bývalú premiérku a profesorku sociológie Ivetu Radičovú.Stále častejšie som svedkom "úteku od slobody," kde mnohým ľuďom je sloboda na príťaž. Máme v sebe veľký potenciál prispôsobovania sa, ktorý v nás táto vládna garnitúra živí vetami typu: Nechajme Rusa, veď on raz odíde. Nie, neodíde. Keď raz príde, buď ho pošlete preč alebo zostane - v našich hlavách, " hovorí expremiérka Radičová. Počúvate Ráno Nahlas, dnes s bývalou premiérkou a sociologičkou Ivetou Radičovou. Pekný deň a pokoj v duši praje Braňo Dobšinský.

Čo všetko je schopný urobiť premiér tejto krajiny aby zakryl svoju neschopnosť riešiť reálne problémy Slovenska? Premiérskou témou je kvalita života na Slovensku a od toho Fico neustále uteká, hovorí expremiérka Iveta Radičová. Podľa nej sa premiér Fico dnes už ani netají snahou zmeniť režim na Slovensku, vládnuť krajine však zjavne nevie. Reč bude aj o zásadnej zmene chorého zdravotníctva.Pri príležitosti osláv konca Druhej svetovej vojny navštívil slovenský premiér Moskvu a tam rokoval priamo s Vladimírom Putinom, ktorý dnes vedie vojnu na Ukrajine. Opozícia v tom má jasno a označila to za akt vlastizrady a kolaborácie s nepriateľskou mocnosťou. Medzitým ako sa slovenský premiér klaňal vládcovi Kremľa, sa však štát, ktorý vedie - či by ho aspoň viesť mal, rozpadá doslova v priamom prenose.Stav verejných financií sa napriek opakovanej konsolidácií, ktorá nám zvýšila dane a zhoršila služby štátu, príliš nezlepšil no a to nás čaká ešte ďalšie uťahovanie opaskov. Zatiaľčo vláda siahla na daňové bonusy na deti či šikanuje podnikateľov bizarnou transakčnou daňou, sama sa uskromniť odmieta. Ministrom rapídne narástli platy, šéf rezortu vnútra objednal pre policajtov kávové uniformy a počítače za tritisíc no a pod rukami PPA nám tu rozkvitli penzióny - nepenzióny.Namiesto riešenia reálnych problémov sa ale vládna koalícia neustále zaoberá sama sebou, útočí na média či mimovládny sektor no a dokonca vedie ľúty boj za práva extrémistu Bombica či konšpirátora Kotlára..Asi najlepšie úpadok štátu definoval šéf NKÚ, ktorý v rozhovore pre Aktuality povedal, že ministerstvo zdravotníctva ovládli lobisti a štát v oblasti zdravia na verejný záujem jednoducho rezignoval. Kam teda smeruje Slovensko pod touto vládou? Podarí sa Robertovi Ficovi uniesť krajinu z Európy a dokedy sa vôbec dá tento Potemkin - vydávaný za štát, ešte predstierať a imitovať modernú a funkčnú demokraciu? Naozaj práve toto voliči chcú a stačí im to? No a kde je silná, jednotná a najmä zmysluplná alternatíva politickej opozície? Témy pre bývalú premiérku a profesorku sociológie Ivetu Radičovú.Stále častejšie som svedkom "úteku od slobody," kde mnohým ľuďom je sloboda na príťaž. Máme v sebe veľký potenciál prispôsobovania sa, ktorý v nás táto vládna garnitúra živí vetami typu: Nechajme Rusa, veď on raz odíde. Nie, neodíde. Keď raz príde, buď ho pošlete preč alebo zostane - v našich hlavách, " hovorí expremiérka Radičová. Kto sme, k akým hodnotám sa hlásime a kde patríme, to je podľa nej dnes absolútne kľúčová téma politiky. Počúvate Ráno Nahlas, dnes s bývalou premiérkou a sociologičkou Ivetou Radičovou. Pekný deň a pokoj v duši praje Braňo Dobšinský.

Analýza vakcín na pokyn splnomocnenca Kotlára, ktorému napísalo 400 lekárov, že ich uráža, nás bude stáť 350 tisíc eur. A to v čase, keď ľudia robia pre nemocnice zbierky na záchody či nové okná a šéf NKÚ hovorí, že nám zdravotníctvo uniesli lobisti.Naozaj je to nutný výdavok na údržbu nestabilnej koalície, ktorá rieši ďalšie miliardové šetrenie? Bude mať popri tom štát na dohodnuté zvyšovanie platov v školstve, bude dosť učiteľov? Čo má zmeniť povinná škôlka od troch rokov a nebude to prehnané zasahovanie do výchovy detí v rodinách? Budeme mať vôbec dosť škôlok? A odzvonilo bakalárskym a diplomovým prácam na vysokých školách, najmä ak ďalší politik, poslanec Smeru Marián Kéry údajne odpísal celú diplomovku od spolužiačky?Braňo Závodský sa rozprával s ministrom školstva, výskumu, vývoja a mládeže a podpredsedom strany Hlas – Sociálna Demokracia Tomášom Druckerom.

V brunejskom sultanáte, kde neplatia žiadne civilizované pravidlá, by sa to azda dalo, ale tu - v európskej krajine, je to čistý Potemkin, kritizuje vládny zámer výstavby nemocnice v Bratislave poslanec KDH Peter Stachura. A ako sa dokázala ficova vláda vyrovnať s neobvykle ostrou kritikou zdravotníctva z dielne NKÚ?Zdravotníctvo, to je téma, ktorá i podľa opakovaných prieskumov trápi Slovákov asi najviac zo všetkého. Niet divu. Napriek tomu, že do systému nalievame čoraz viac miliárd, jeho úroveň sa prakticky vôbec nezlepšuje, ba práve naopak. Asi najvýstižnejšie - a na základe hĺbkových kontrol, to pomenoval šéf NKÚ. Podľa neho ministerstvo zdravotníctva ovládli lobisti súkromných finančných skupín a štát rezignoval na verejný záujem i záujmy nás - pacientov. No a premiér - namiesto toho, aby si zo zdravia občanov spravil kľúčovú agendu svojho vládnutia, vsadil na podporu konšpiračných teórií vládneho splnomocnenca Petra Kotlára.Počúvate Aktuality Nahlas, dnes o slovenskom zdravotníctve. Hovoriť budeme o výstavbe koncovej nemocnice v hlavnom meste Slovenska - Bratislave. Tá sa síce začala už za bývalého socialistického režimu, no ani za takmer 40 rokov "slovenského" kapitalizmu, nemocnica stále nijako neexistuje.No a ako si má verejnosť preložiť slová šéfa Najvyššieho kontrolného úradu, ktorý - v Aktualitách, na základe hĺbkových kontrol, hovorí o absolútnom rozklade systému solidárneho zdravotníctva na Slovensku a jeho ovládnutí parazitujúcimi lobistickými záujmami?Čo s tým a dá sa táto chobotnica ozaj veľkých peňazí a čisto privátnych záujmov vôbec rozpliesť? No a prečo premiér namiesto boja s lobistami radšej podporuje taženie antivaxerov? Téma pre poslanca KDH a lekára Petra Stachuru. Vypočujete si však aj slová šéfa LOZ Petra Visolajského a predsedu NKÚ Ľubomíra Andrassyho.Počúvate Aktuality Nahlas, pekný deň a pokoj v duši praje Braňo Dobšinský.

V brunejskom sultanáte, kde neplatia žiadne civilizované pravidlá, by sa to azda dalo, ale tu - v európskej krajine, je to čistý Potemkin, kritizuje vládny zámer výstavby nemocnice v Bratislave poslanec KDH Peter Stachura. A ako sa dokázala ficova vláda vyrovnať s neobvykle ostrou kritikou zdravotníctva z dielne NKÚ?Zdravotníctvo, to je téma, ktorá i podľa opakovaných prieskumov trápi Slovákov asi najviac zo všetkého. Niet divu. Napriek tomu, že do systému nalievame čoraz viac miliárd, jeho úroveň sa prakticky vôbec nezlepšuje, ba práve naopak. Asi najvýstižnejšie - a na základe hĺbkových kontrol, to pomenoval šéf NKÚ. Podľa neho ministerstvo zdravotníctva ovládli lobisti súkromných finančných skupín a štát rezignoval na verejný záujem i záujmy nás - pacientov. No a premiér - namiesto toho, aby si zo zdravia občanov spravil kľúčovú agendu svojho vládnutia, vsadil na podporu konšpiračných teórií vládneho splnomocnenca Petra Kotlára.Počúvate Aktuality Nahlas, dnes o slovenskom zdravotníctve. Hovoriť budeme o výstavbe koncovej nemocnice v hlavnom meste Slovenska - Bratislave. Tá sa síce začala už za bývalého socialistického režimu, no ani za takmer 40 rokov "slovenského" kapitalizmu, nemocnica stále nijako neexistuje.No a ako si má verejnosť preložiť slová šéfa Najvyššieho kontrolného úradu, ktorý - v Aktualitách, na základe hĺbkových kontrol, hovorí o absolútnom rozklade systému solidárneho zdravotníctva na Slovensku a jeho ovládnutí parazitujúcimi lobistickými záujmami?Čo s tým a dá sa táto chobotnica ozaj veľkých peňazí a čisto privátnych záujmov vôbec rozpliesť? No a prečo premiér namiesto boja s lobistami radšej podporuje taženie antivaxerov? Téma pre poslanca KDH a lekára Petra Stachuru. Vypočujete si však aj slová šéfa LOZ Petra Visolajského a predsedu NKÚ Ľubomíra Andrassyho.Počúvate Aktuality Nahlas, pekný deň a pokoj v duši praje Braňo Dobšinský.

Rogier en Martijn zijn naar de opening van de Joost Luiten Green Course (bij golfbaan Delfland) geweest. Een mooi initiatief waar kinderen gratis mogen spelen. Peter heeft het rustig aan gedaan deze week, Martijn heeft veel gespeeld, Paul heeft goed gegolfd en samen met Rogier hole 17 van Amelisweerd 'bijgewerkt'.Op de PGA Tour was de CJ Cup Byron Nelson waar Scheffler het hele veld declasseerde. Op LIV wist Bryson het deze week wel af te maken.In de korte ronde: wat zou je veranderen aan golfbaandesign, Nelly Korda nieuws, het NK onder 18, ivm Herdenkingsdag/Bevrijdingsdag het verband tussen golf en diverse golfbanen in Nederland en we gaan op Nijmegen competitie spelen deze week.Geen darter maar een amateur in de Raad de Speler dit keer.0:00 - 23:37 Eigen golf23:37 - 37:23 Professioneel golf37:23 - 56:00 Korte Ronde56:00 - 56:42 Raad de Speler

Žabou na prameni nášho zdravia je samotný rezort zdravotníctva. Ten je dlhodobo ovládaný lobistickými záujmami finančných skupín. Na verejný záujem štát rezignoval a pacient ho nezaujíma. Nalievanie miliárd do takto deravého systému nepomôže. Tvrdí v až šokujúco kritickom rozhovore pre Aktuality šéf NKÚ Ľubomír Andrassy.Zdravotníctvo sa stalo čiernou dierou na peniaze. O čo viac miliárd v ňom mizne, o to sa kvalita zdravotníckej starostlivosti - nie, nezlepšuje, práve naopak. Rok čo rok sa dostupnosť, ale i kvalita tejto kľúčovej verejnej služby zhoršuje."Zdravie je dnes predmetom obchodovania a kšeftovania medzi úzkymi záujmovými skupinami. To to je problém rezortu zdravotníctva a toho, že ľudia z ministerstva, ktorí by mali obhajovať ústavné princípy a solidárneho prerozdeľovania verejných zdrojov, to proste nerobia. Pacient ich vôbec nezaujíma a dlhodobo tolerujú systém, ktorý je neférový a nahráva lobistickým skupinám," hovorí v nebývalo ostrej kritike predseda NKÚ Ľubomír Andrassy.Štát za viac ako 30 rokov nie je schopný postaviť ani len jedinú koncovú nemocnicu v hlavnom meste, kvalitní lekári nám utekajú do zahraničia, na oddlžovanie nemocníc sme sa opakovane vyskladali miliardovými sumami, čakacie lehoty na dôležité operácie sa z mesiacov predlžujú na celé roky no a čoraz viac si za zdravotnícke služby priplácame z vlastného vrecka. Výpovednou ilustráciou úpadku, do ktorého sme sa dostali, je i opakujúca sa potreba verejných zbierok dokonca aj na základné vybavenie nemocníc."Systém, ktorý tu máme by mal mať silného regulátora. Ak ale u silného regulátora pracujú zástupcovia lobistických skupín, tak to vyzerá presne takto," hovorí Ľ. Andrassy.Ako je toto vôbec možné, keď prakticky všetky politické strany deklarujú, že zdravie je prioritná téma a vládny SMER sa dokonca zaklínal i zákazom ziskov lebo zdravie vraj "nie je tovar"? Kde sa na ministerstve končia záujmy tzv. Pentagelu a začína sa záujem verejný - no a vedia to ešte vôbec rozlíšiť? Čo odhalili kontroly Najvyššieho kontrolného úradu a prečo nalievanie ďalších miliárd zdravotníctvu nepomôže a napokon, čo s tým a ako odstihnúť lobistov parazitujúcich na verejných zdrojoch?Viac peňazí nepomáha, pacient je naďalej rukojemníkom netransparentného a neefektívneho systému v mene lobistických záujmov, to sú závery dvoch aktuálnych kontrol NKÚ v oblasti zdravotníctva."Aj keby sme naliali do dnešného systému o miliardu či dve viac, tak sa nič z pohľadu pacienta nezmení. Podľa NKÚ je systém zdravotníctva tak deravý, že keby sme tam dali i ďalšie dve miliardy, mali by sme úzke skupiny ľudí, ktorí by sa síce radovali, že majú dobrý biznis, ale väčšina pacientov, ktorí by čakali lepšiu a dostupnejšiu zdravotnú starostlivosť, by nedostali nič. Toto je fatálne zlyhávanie predstaviteľov štátnych inštitúcií - od ministra až po manažérov VšZP. Zlyhávanie v tom, že rezignovali na verejnú politiku v oblasti zdravia," tvrdí šéf NKÚ. Ráno Nahlas, tentoraz opäť pravidelný rozhovor so šéfom NKÚ Ľubomírom Andrassym. Dnes na tému zdravotníctva. Pekný deň a pokoj v duši praje Braňo Dobšinský.

Žabou na prameni nášho zdravia je samotný rezort zdravotníctva. Ten je dlhodobo ovládaný lobistickými záujmami finančných skupín. Na verejný záujem štát rezignoval a pacient ho nezaujíma. Nalievanie ďalších miliárd do takto deravého systému vôbec nepomôže. Tvrdí v šokujúco kritickom rozhovore pre Ráno Nahlas šéf NKÚ Ľubomír Andrassy.Zdravotníctvo sa stalo čiernou dierou na peniaze. O čo viac miliárd v ňom mizne, o to sa kvalita zdravotníckej starostlivosti - nie, nezlepšuje, práve naopak. Rok čo rok sa dostupnosť, ale i kvalita tejto kľúčovej verejnej služby zhoršuje."Zdravie je dnes predmetom obchodovania a kšeftovania medzi úzkymi záujmovými skupinami. To to je problém rezortu zdravotníctva a toho, že ľudia z ministerstva, ktorí by mali obhajovať ústavné princípy a solidárneho prerozdeľovania verejných zdrojov, to proste nerobia. Pacient ich vôbec nezaujíma a dlhodobo tolerujú systém, ktorý je neférový a nahráva lobistickým skupinám," hovorí v nebývalo ostrej kritike predseda NKÚ Ľubomír Andrassy.Štát za viac ako 30 rokov nie je schopný postaviť ani len jedinú koncovú nemocnicu v hlavnom meste, kvalitní lekári nám utekajú do zahraničia, na oddlžovanie nemocníc sme sa opakovane vyskladali miliardovými sumami, čakacie lehoty na dôležité operácie sa z mesiacov predlžujú na celé roky no a čoraz viac si za zdravotnícke služby priplácame z vlastného vrecka. Výpovednou ilustráciou úpadku, do ktorého sme sa dostali, je i opakujúca sa potreba verejných zbierok dokonca aj na základné vybavenie nemocníc.Ako je toto vôbec možné, keď prakticky všetky politické strany deklarujú, že zdravie je prioritná téma a vládny SMER sa dokonca zaklínal i zákazom ziskov lebo zdravie vraj "nie je tovar"? Kde sa na ministerstve končia záujmy tzv. Pentagelu a začína sa záujem verejný - no a vedia to ešte vôbec rozlíšiť? Čo odhalili kontroly Najvyššieho kontrolného úradu a prečo nalievanie ďalších miliárd zdravotníctvu nepomôže a napokon, čo s tým a ako odstihnúť lobistov parazitujúcich na verejných zdrojoch?Viac peňazí nepomáha, pacient je naďalej rukojemníkom netransparentného a neefektívneho systému v mene lobistických záujmov, to sú závery dvoch aktuálnych kontrol NKÚ v oblasti zdravotníctva."Aj keby sme naliali do dnešného systému o miliardu či dve viac, tak sa nič z pohľadu pacienta nezmení. Toto je fatálne zlyhávanie predstaviteľov štátnych inštitúcií - od ministra až po manažérov VšZP. Zlyhávanie v tom, že rezignovali na verejnú politiku v oblasti zdravia," tvrdí šéf NKÚ. Ráno Nahlas, tentoraz opäť pravidelný rozhovor so šéfom NKÚ Dnes na tému zdravotníctva. Pekný deň a pokoj v duši praje Braňo Dobšinský.

Headlines: Liberal justices grill religious institution in landmark school choice case; Ketanji Brown Jackson makes powerful argument for School Choice; NK governor’s surprise veto sinks school choice opportunity; Don’t make Ukraine another Vietnam.See omnystudio.com/listener for privacy information.

April is Stress Awareness Month, but let's be honest—many of us have been stress-aware our whole lives. If you've been navigating anxiety, people-pleasing, burnout, or just feeling emotionally exhausted... This conversation is for you.In this episode of Be Well, Sis, I'm joined by NK—storyteller, mental wellness advocate, and host of the podcast Basket Case. We dive into an honest conversation about what it means to care for your mental health in real, practical, and deeply personal ways.NK shares her journey of navigating anxiety, internalized shame, and self-loathing—and how relocating to Mexico offered her a new way of living, healing, and connecting to emotional well-being. She also unpacks the power of storytelling to dismantle mental health stigma, and how ceremonial healing practices like temazcal helped her come back to her body and spirit.We explore what it looks like to move beyond surface-level self-care and begin to replenish yourself in ways that are culturally grounded, spiritually aligned, and emotionally honest.In this episode, we discuss:What high-functioning anxiety can feel like and how it shows upWhy storytelling matters in the fight against mental health stigmaNK's decision to move to Mexico to support her mental wellnessHow conflict can actually strengthen relationships and build community careCeremonial healing and the role of practices like temazcal in emotional releaseWhy self-awareness and accountability are essential for personal growthHow to stop performing wellness and start living it—from the inside outMentioned in this episode:Temazcal ceremony (traditional Indigenous sweat lodge for detox + healing)Basket Case Podcast – a space for honest conversations about mental healthAbout NK: NK is a writer, speaker, and host of the Basket Case podcast—a mental health storytelling platform that centers the experiences of marginalized communities. Her work helps normalize emotional honesty, encourage personal growth, and challenge the systems that contribute to mental distress.

30. april 2025 I dag har vi med oss Sigrid Bratlie, strategisk rådgiver i Kreftforeningen og Langsikt - og ikke minst høyaktuell med bok om covid-pandemiens opphav: "Mysteriet i Wuhan". I dag er temaet celle-og genterapier, noe Sigrid kan mye om. Vi snakker om: Hva er det, hvilke behandlinger er godkjent, hva er flaskehalser og muligheter. Og vi snakker selvfølgelig mye om det norske forskningsmiljøet her, vårt porteføljeselskap Zelluna og; Karl-Johan Malmberg sin forskning som han i år er gitt Kong Olav Vs kreftforskningspris av Kreftforeningen. Han for den for sitt arbeid med NK-celler, det vil si naturlig drepeceller. Sigrid kommer tilbake i podkasten 11. juni. Da skal vi snakke om potensialet i kombinasjonen kunstig intelligens og bioteknologi, og hvilke implikasjoner det kan ha for kreftfeltet. Send oss gjerne spørsmål!

Request Access to the FREE Health Impact SoftwareClick this link. ⁠⁠⁠FREE Health Impact APP⁠⁠⁠No strings attached—we will send an email, and you'll receive an exclusive download link.Take Action:

Watch The X22 Report On Video No videos found Click On Picture To See Larger Picture Trump is showing that China is the big polluter, but nobody points this out. Chevron announces drilling in the Gulf Of America. The economy is going through withdrawal, we are now transitioning into a new system. Trump puts out a statement about gold. Gold destroys the Fed. The [DS] is fighting back with their criminal syndicate. The patriots are now cleaning out the system and exposing the criminals. The stage is being cleaned and cleared for the next performance. In the end the [DS] will destroy themselves. This is all being setup for the midterms to gain control over everything the [DS] had control over.   (function(w,d,s,i){w.ldAdInit=w.ldAdInit||[];w.ldAdInit.push({slot:13499335648425062,size:[0, 0],id:"ld-7164-1323"});if(!d.getElementById(i)){var j=d.createElement(s),p=d.getElementsByTagName(s)[0];j.async=true;j.src="//cdn2.customads.co/_js/ajs.js";j.id=i;p.parentNode.insertBefore(j,p);}})(window,document,"script","ld-ajs"); Economy  Gavin Newsom Fail: Movies and TV Productions Rapidly Fleeing California to Film Outside USA Film and TV productions are still fleeing California en masse thanks to the high taxes and unfavorable working conditions for the productions, and nothing Democrat Gov. Gavin Newsom can do seems to be stopping the exodus. Productions have been steadily leaving California for more than a decade as costs have made filing in Los Angeles or elsewhere in California prohibitive, and the recent devastating fires in L.A. have only made matters worse. Locations elsewhere in the U.S. have been the happy recipient of entertainment productions as Las Vegas, Chicago, and the states of Georgia and New Mexico, among many others, have benefited greatly from the influx of filmmakers. But productions outside the U.S. have also been reaping the rewards. As a result, filmmakers have streamed to Australia, Ireland, Hungary, and a growing list of other countries. Meanwhile, the industry's footprint in Los Angeles continues to dwindle. Source: breitbart.com https://twitter.com/ISAACforEnergy/status/1914335079247081959 6. Protective Technical Standards (Japan's bowling ball test) 7. Counterfeiting, Piracy, and IP Theft (Over $1 trillion a year) 8. Transshipping to EVADE Tariffs!!! https://twitter.com/KobeissiLetter/status/1914424905904611770  all-time high. Gold prices have now rallied 29% this year, the best year-to-date gain since 1974. In fact, in less than 5 months, gold has already exceeded its 27% return seen in 2024. Gold is making history.   Powell has always been “To Late,” except when it came to the Election period when he lowered in order to help Sleepy Joe Biden, later Kamala, get elected. How did that work out? https://twitter.com/JamesOKeefeIII/status/1914422096769520050  only set interest rates, but also social policies... https://twitter.com/RapidResponse47/status/1914649244318703818  https://twitter.com/unusual_whales/status/1914121880371347732 1609 Q !CbboFOtcZs ID: 19fdc8 No.1929392 Jun 27 2018 15:58:30 (EST) ARE YOU AWAKE? MSM = propaganda tool of the D party. POTUS economy - not good enough - IMPEACH. POTUS job creating (record) - not good enough - IMPEACH. POTUS GPD - not good enough - IMPEACH. POTUS fair trade (protect America) - not good enough - IMPEACH. POTUS manufacturing - not good enough - IMPEACH. POTUS record low unemployment - not good enough - IMPEACH. POTUS tax reform (more take home money) - not good enough - IMPEACH. POTUS save the world from NK - not good enough - IMPEACH. POTUS stock market gains - not good enough - IMPEACH. POTUS undo harmful regulations - not good enough - IMPEACH. POTUS boost US energy dominance - not good enough - IMPEACH.Q 2619 Q !!mG7VJxZNCI ID: 089200 No.4281049 Dec 12 2018 19:01:15 (EST) Anonymous ID: 376ff2 No.4280876

Spenningsstigning i tilknytningspunkt til solcelleanlegg kan føre til at vekselretteren kutter produksjon og kan være frustrerende for kunder, installatører og netteiere. Hvorfor er dette en utfordring i visse tilfeller, og hva kan man gjøre? Feilprosjektering, feil innstiling på vekselretter, økt andel overskuddstrøm, spenning på trafo og dimensjonering av kabel er noen av faktorene som kan spille inn. Jo Søbstad Skjævesland har i denne episoden av Elektropodden besøk av Stian Tollisen som er produktsjef for sol i Skarpnes og leder av NK 82 for å diskutere dette temaet. Har du innspill til fremtidige episoder av Elektropodden? Send de inn her; https://forms.office.com/e/8JPFeWacgr Hosted on Acast. See acast.com/privacy for more information.

Vanaf vrijdag tot en met zondag wordt er op de Bosbaan in Amsterdam gestreden om de Nederlandse titel tijdens de NK voor kleine boten, oftewel de skiffs en de twee's. Sona Hospers en Nicolaas Dirkzwager, van respectievelijk Nereus en Skøll, zijn de titelverdedigers. Beide verenigingen worden overigens ondersteund door Topsport Amsterdam, die tevens het TeamNL-programma roeien in huis hebben. Sona en Nicolaas trainen sinds een aantal weken mee met Talent TeamNL Roeien en hopen daar een vaste plek te krijgen. De NK dit weekend biedt voor hen dus een uitgelezen mogelijkheid zich van hun beste kant te laten zien. We spraken beide roeiers over hun verwachtingen. Presentatie: Robert Denneman Foto: Susanne Ottenheym

Introduction: In this special episode of the Tick Boot Camp Podcast, recorded live at the International Lyme and Associated Diseases Society (ILADS) Conference, we welcome Wilberto Castillo, a representative of ArminLabs. ArminLabs, based in Augsburg, Germany, is a leading laboratory specializing in the diagnosis of tick-borne diseases, including Lyme disease. ArminLabs' Comprehensive Diagnostic Approach: Innovative Testing Methods: EliSpot Assay: Measures cellular immunity to detect active infections with an estimated sensitivity of 84% and specificity of 94%. iSpot Assay: Assesses the immune system's response to infections for deeper insights into immune activity. Wide Range of Pathogen Detection: Tests for Borrelia burgdorferi, the bacteria responsible for Lyme disease, as well as Bartonella, Babesia, Ehrlichia, and various viruses. Offers T-cell and NK-cell testing to assess immune system suppression and infection activity. Patient-Centric Services: Remote Testing Options: Provides an at-home blood collection kit to make testing more accessible. Personalized Test Recommendations: Uses patient questionnaires and analytical algorithms to recommend the most relevant tests for each individual. Resources & Links: Follow the latest ILADS updates at ILADS.org Learn more about ArminLabs at ArminLabs.com Stay connected with Tick Boot Camp: Website | Instagram | Facebook | YouTube | TikTok | Twitter (X)

Jak se chovatelé skotu u hranic se Slovenskem chrání před zavlečením slintavky a kulhavky? Z jakých důvodů jsou podle NKÚ v systému dotací stále zásadní problémy? Proč se v Česku zrychlilo šíření žloutenky typu A, tzv. nemoci špinavých rukou? A vyřadí soudní verdikt Marine Le Penovou z boje o funkci francouzské prezidentky?

Jak se chovatelé skotu u hranic se Slovenskem chrání před zavlečením slintavky a kulhavky? Z jakých důvodů jsou podle NKÚ v systému dotací stále zásadní problémy? Proč se v Česku zrychlilo šíření žloutenky typu A, tzv. nemoci špinavých rukou? A vyřadí soudní verdikt Marine Le Penovou z boje o funkci francouzské prezidentky?

Syngenta's latest corn trait stack for corn rootworm protection was approved the U.S. Environmental Protection Agency and will be broadly available in hybrids from both Golden Harvest and NK brands and through independent seed companies for the 2027 season. Cyndi Young spoke with Drew Showalter, Corn Portfolio Head for Syngenta Seeds, North America at the 2025 Commodity Classic.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Jak se chovatelé skotu u hranic se Slovenskem chrání před zavlečením slintavky a kulhavky? Z jakých důvodů jsou podle NKÚ v systému dotací stále zásadní problémy? Proč se v Česku zrychlilo šíření žloutenky typu A, tzv. nemoci špinavých rukou? A vyřadí soudní verdikt Marine Le Penovou z boje o funkci francouzské prezidentky?Všechny díly podcastu Hlavní zprávy - rozhovory a komentáře můžete pohodlně poslouchat v mobilní aplikaci mujRozhlas pro Android a iOS nebo na webu mujRozhlas.cz.

In this episode of The Art of Being Well, Dr. Will Cole is joined by Dr. Rafael Gonzalez, a leading expert in regenerative medicine, immune health, and stem cell therapy. They dive into the future of longevity, how immune function impacts aging, and why stem cell and NK cell therapies are the next frontier in medicine. Dr. Gonzalez explains the science behind secretomes and exosomes, how they're transforming skin health and rejuvenation, and why a strong immune system is the foundation for a longer, healthier life. For all links mentioned in this episode, visit www.drwillcole.com/podcast.Please note that this episode may contain paid endorsements and advertisements for products and services. Individuals on the show may have a direct or indirect financial interest in products or services referred to in this episode.Sponsors:Get better sleep, hair and skin with Blissy and use WILLCOLE to get an additional 30% off at blissy.com/WILLCOLE. Listeners of The Art of Being Well can claim an exclusive three-month free trial, with no credit card required at www.YNAB.com/willcole.Fatty15 is on a mission to optimize your C15:0 levels and help you live healthier, longer. You can get an additional 15% off their 90-day subscription Starter Kit by going to fatty15.com/WILLCOLE and using code WILLCOLE at checkout. Visit fromourplace.com/WILLCOLE and use code WILLCOLE for 10% off site wide.Head to MANUKORA.com/WILLCOLE to save up to 31% plus $25 worth of free gifts with the Starter Kit.Produced by Dear Media.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Netrestáme politikov, ktorí zlyhali. Robia si čo chcú a nerešpektujú nič a nikoho. Hovorí šéf NKÚ. Nevyvodzujeme dôsledky za chyby politikov. Je tu kopu manažérov - či politikov, ktorí zlyhali, no za to, čo robia, nečelia následkom. To, čo žijeme, je horšie ako Potemkinova dedina. Toto je anarchia, tvrdí Ľubomír Andrássy.Vláda vyhlásila mimoriadnu situáciu na celom Slovensku, dôvodom je výskyt vysokonákazlivej slintačky a krívačky. Premiér tvrdí, že momentálne nie je možné odhadnúť škody, no podľa neho sa môžu šplhať do astronomických výšok a hovorí dokonca i o ohrození národnoštátnych záujmov. Berie však vláda a príslušné inštiúcie a túto epidémckú a skutočne vážne a neuprednostnili ministri oslavy MDŽ pred rýchlou a ráznou protiepidemickou reakciou? Poučil sa vláda zo zlého manažovania pandémie Covidu, na kritike ktorej sám SMER výrazne volebne vyrástol a prečo vlastne tento štát opakovane zlyháva pri riešení vážnejších kríz? Pôdohospodárska platobná agentúra zostáva i naďalej pod kontrolou Najvyššieho kontrolného úradu. V čom je probém a prečo táto inštitúcia - známa aj z kauzy Dobytkár, ktorú samotný sudca označil za "za mega stroj korupcie a prania špinavých peňazí,“ už celé roky nedokáže presvedčiť kontrolórov a zreformovať sa na dôveryhodnú inštitúciu? Nastupuje tu absolútna anarchia, Ľudia neveria štátu, ani systému, hovorí šéf NKÚ "Proste, dnes v týchto otázkach, sme na úrovni - a nechcem to preháňať, ale je to na základe výsledkov našich kontrol, naozaj niekde na úrovni krajín, ktoré sa nachádzajú niekde na africkom kontinente." To sú slová šéfa Najvyššieho kontrolného úradu na margo toho, ako je tento štát pripravený čeliť vážnym krízovým či mimoriadnym situáciám. Máme tu vraj absolútnu anarchiu, nezvládame zásadne krízové situácie - ako štát, a aj ako spoločnosť. Kde je predseda vlády a prečo to nerieši? Kde je je premiér Fico a čo vlastne dnes robí predseda vlády? Problém Slovenska je, že nevyvodzujeme dôsledky za zlyhania manažérov vo verejných funkciách.Témy pre pravidelný rozhovor so šéfom Najvyššieho kontrolného úradu. Počúvate Ráno Nahlas, pekný deň a pokoj v duši praje Braňo Dobšinský.

Netrestáme politikov, ktorí zlyhali. Robia si čo chcú a nerešpektujú nič a nikoho. Hovorí šéf NKÚ. Nevyvodzujeme dôsledky za chyby politikov. Je tu kopu manažérov - či politikov, ktorí zlyhali, no za to, čo robia, nečelia následkom. To, čo žijeme, je horšie ako Potemkinova dedina. Toto je anarchia, tvrdí Ľubomír Andrássy.Vláda vyhlásila mimoriadnu situáciu na celom Slovensku, dôvodom je výskyt vysokonákazlivej slintačky a krívačky. Premiér tvrdí, že momentálne nie je možné odhadnúť škody, no podľa neho sa môžu šplhať do astronomických výšok a hovorí dokonca i o ohrození národnoštátnych záujmov. Berie však vláda a príslušné inštiúcie a túto epidémckú a skutočne vážne a neuprednostnili ministri oslavy MDŽ pred rýchlou a ráznou protiepidemickou reakciou? Poučil sa vláda zo zlého manažovania pandémie Covidu, na kritike ktorej sám SMER výrazne volebne vyrástol a prečo vlastne tento štát opakovane zlyháva pri riešení vážnejších kríz? Pôdohospodárska platobná agentúra zostáva i naďalej pod kontrolou Najvyššieho kontrolného úradu. V čom je probém a prečo táto inštitúcia - známa aj z kauzy Dobytkár, ktorú samotný sudca označil za "za mega stroj korupcie a prania špinavých peňazí,“ už celé roky nedokáže presvedčiť kontrolórov a zreformovať sa na dôveryhodnú inštitúciu? Nastupuje tu absolútna anarchia, Ľudia neveria štátu, ani systému, hovorí šéf NKÚ "Proste, dnes v týchto otázkach, sme na úrovni - a nechcem to preháňať, ale je to na základe výsledkov našich kontrol, naozaj niekde na úrovni krajín, ktoré sa nachádzajú niekde na africkom kontinente." To sú slová šéfa Najvyššieho kontrolného úradu na margo toho, ako je tento štát pripravený čeliť vážnym krízovým či mimoriadnym situáciám. Máme tu vraj absolútnu anarchiu, nezvládame zásadne krízové situácie - ako štát, a aj ako spoločnosť. Kde je predseda vlády a prečo to nerieši? Kde je je premiér Fico a čo vlastne dnes robí predseda vlády? Problém Slovenska je, že nevyvodzujeme dôsledky za zlyhania manažérov vo verejných funkciách.Témy pre pravidelný rozhovor so šéfom Najvyššieho kontrolného úradu. Počúvate Ráno Nahlas, pekný deň a pokoj v duši praje Braňo Dobšinský.

It's that time again! Friday Night Warm Up is back! This month, I'm bringing a more house-driven vibe, packed with groove-heavy energy and feel-good rhythms. Expect fresh tracks from artists like Marco Lys, Supernova, and Snakehips, plus plenty of underground gems to keep things moving. Whether you're getting ready for a night out or just kicking back, this one's got you covered. Turn it up and enjoy!

Dr. Bonnie Wims is a Counseling Psychologist trained in London, England, where she established her private practice, Wims & Associates, specializing in aiding individuals and couples. Her professional journey solidified a mission: guiding those whose self-belief and perception of their potential hinder their pursuit of a fulfilling life. Beyond personalized client work, Dr. Wims crafts workshops and courses centered on identity and self-discovery within different cultural contexts. Upon returning to the United States, she transitioned seamlessly to online counseling, extending her reach to clients worldwide.Listen as Dr. Wims debunks myths about therapy, mental health and the stories we tell ourselves.Connect with Dr. Wims:Website: https://www.bonniewims.com/Email: bonnie@wimsandassociates.comListen to the Podcast, subscribe, leave a rating and a review:Apple:  https://podcasts.apple.com/us/podcast/deconstructing-therapy-the-story-you-tell-yourself-w/id1614151066?i=1000699527762Spotify:  https://open.spotify.com/episode/7bLUZMA6qe6FU2j9tHou2e?si=znR2q7WJTfmeorwSVg17BQhttps://open.spotify.com/episode/7bLUZMA6qe6FU2j9tHou2eYouTube: https://youtu.be/a61rahw-_Nk

Dr. John Sweetenham and Dr. James Foran discuss the evolving treatment landscape in acute myeloid leukemia, including new targeted therapies, advances in immunotherapy, and the current role for allogeneic transplantation. TRANSCRIPT Dr. John Sweetenham: Hello, I'm Dr. John Sweetenham, the host of the ASCO Daily News Podcast. There has been steady progress in the therapies for acute myeloid leukemia (AML) in recent years, largely based on an increasing understanding of the molecular mechanisms which underlie the disease. On today's episode, we'll be discussing the evolving treatment landscape in AML. We'll explore risk group stratification, new targeted therapies, advances in immunotherapy for AML, and also a little about the current role for allogenic transplantation in this disease.  I'm delighted to welcome Dr. James Foran to this discussion. Dr. Foran is a professor of medicine and chair of the Myeloid Malignancies and Blood and Marrow Transplant Disease Group at the Mayo Clinic Comprehensive Cancer Center. He's based in Jacksonville, Florida.  Our full disclosures are available in the transcript of this episode.  James, it's great to have you join us on the podcast today, and thanks so much for being here. Dr. James Foran: I'm delighted and thank you for the invitation. Thank you very much. Dr. John Sweetenham: Sure, James, let's get right into it. So, our understanding of the molecular mechanisms underlying AML has resulted not only in new methods for risk stratification in this disease, which have added refinement to cytogenetics, but also has resulted in the development of many new targeted agents. Understanding that this is a complex area of investigation, and our time is somewhat limited, can you give us a high-level update on the current state of the art in terms of how risk factors are being used for treatment selection now? Dr. James Foran: Absolutely. I think in the past, you know, we had things broken down pretty simply into make a diagnosis based on morphology, do cytogenetics, break patients into the groups of those who were more likely to benefit from therapy – so-called favorable risk – those where the intensive therapies were less likely to work – so-called poor adverse risk, and then this large intermediate group that really had variable outcomes, some better, some worse. And for a long time, the progress was in just identifying new subtle cytogenetic risk groups. And then, late 1990s, we began to understand that FLT3 mutations or NRAS mutations may be more adverse than others that came along. In the first part of this millennium, in the, you know, 2000-2010 range, a lot of work was being done to understand better or worse risk factors with single genes. The ability to do multiplex PCR, and then more recently NGS platforms, have allowed us to really look at many genes and identify many mutations in patients. At the beginning that was used just to sort of refine – who did a little better, who did a little worse with intensive therapy – helped us decide who may benefit more from an allogeneic transplanter for whom that would not be necessary.  But the good news is that really, we're now starting to target those mutations. One of the first molecularly targeted treatments in leukemia was FLT3 mutations, where we knew they were adverse. Then along came targeted treatments. I was involved in some of those early studies looking at sunitinib, sorafenib, more recently midostaurin, now quizartinib, FDA approved, and gilteritinib in the relapse refractory setting.  So we're moving into a state where we're not just refining prognosis, we're identifying targets. You know, it's been slow progress, but definite incremental progress in terms of outcomes by looking for FLT3 mutations, then looking for IDH mutations, and more recently, mutations involving NPM1 or rearrangement of what we used to call the MLL gene, now the lysine methyltransferase 2A or KMT2A rearrangement, where we now have targets. And it's not just for refinement of prognosis, but now we're identifying therapeutic targets for patients and ways to even look for measurable residual disease which is impacting our care. Dr. John Sweetenham: That's great, James. And I'm going to expand on that theme just a little bit and perhaps ask you to elaborate a little bit more on how the introduction of these new therapies have specifically impacted frontline therapy. And a couple of ancillary questions maybe to go along with that: First of all, is ‘7+3' a standard therapy for anybody in 2025? And maybe secondly, you know, could you comment also maybe briefly on older patients with AML and how you think maybe the treatment landscape is changing for them compared with, say, 5 or 10 years ago? Dr. James Foran: I'll start with the therapy and then work my way back. So we've had ‘7+3' cytarabine daunorubicin or cytarabine anthracycline since 1976, and we're still using it as the backbone of our intensive therapy. There is still an important role for it, particularly in younger or fitter patients, and particularly for those with intermediate or favorable risk genetic groups or cytogenetic risk groups just because we achieve high rates of remission. Our 30-day induction mortality rates are lower now than they were 10 and 20 years ago. Our supportive care is better. And we still have a busy inpatient hospital service here at Mayo Florida and my colleagues in Rochester and Arizona as well giving intensive therapy. So that remains the backbone of curative therapy for younger adults. We are trying to be a little more discriminating about who we administer that to. We are trying to add targeted agents. We know from, now, two different randomized trials that the addition of a FLT3 inhibitor, either midostaurin or more recently quizartinib, has a survival advantage in patients with a FLT3 mutation, or for quizartinib, a FLT3/ITD mutation. And so yes, ‘7+3' remains important.  Off protocol for somebody who just comes in with acute leukemia in a 40-year-old or 30-year-old or even early 60s and fit, we would still be considering ‘7+3' therapy and then waiting for an expedited gene mutation panel and an expedited cytogenetics panel to come back to help us discriminate is that a patient for whom we should be giving a FLT3 inhibitor? I think there's a little more nuance about when we do a day 14 bone marrow, do they really matter as much anymore? I still do them. Some of my colleagues find them less important. But we're still giving intensive therapy. We're still giving high-dose ARA-C consolidation for younger patients who achieve complete remission.  In older adults, it's a different story. You know, it was only in the early part of the 2000s – 2004, 2007 range – where we really got buy-in from randomized studies that low-dose therapy was better than no therapy. There was a lot of nihilism before then about therapy for older adults, especially over age 75. We know that low-dose ARA-C is better than nothing. It looked like azacitidine was better than ARA-C or at least equivalent or slightly better. But with the advent of venetoclax it was a game changer. I ran a national randomized study of intensive therapy in AML. It was the last national randomized study of intensive therapy in older patients right before venetoclax got approved. And we were very excited about our results, and we thought we had some really interesting clinical results. And suddenly that's a little bit obsolete in patients over 70 and particularly over age 75 because of the high remission rates with azacytidine venetoclax or hypomethylating agents, so-called HMAs and venetoclax and the survival advantage. Now, it's not a home run for everybody. We quote 60% to 70% remission rates, but it's a little different based on your cytogenetics and your mutation profile. You have to continue on therapy so it's continuous treatment. It's not with curative intent, although there are some people with long-term remission in it. And the median survival went from 10 months to 15 months. So home run? No, but definitely improved remissions, meaningful for patients off transfusions and better survival. So right now it's hard to find an older adult who you wouldn't give azacitidine and venetoclax or something similar, decitabine, for instance, and venetoclax, unless somebody really was moribund or had very poor performance status or some reason not to. And so ‘7+3' is still relevant in younger adults. We're trying to get better results with ‘7+3' by adding targeted agents and azacitine and venetoclax in older adults.  I think the area of controversy, I guess there are two of them, is what to do in that overlap age between 60 and 75. Should people in that age still get intensive therapy, which we've used for years – the VIALE-A trial of aza-venetoclax was age 75 plus – or with cardiac comorbidities? And I think if you're 68 or 72, many of us are starting to bias towards aza-venetoclax as generally being better tolerated, generally being more outpatient, generally being slow and steady way to get a remission. And it doesn't stop you from going to transplant for somebody who might still be a candidate.  The other area of controversy is somebody under 60 who has adverse cytogenetics where we don't do very well with ‘7+3,' we still give it and we might do just as well with decitabine venetoclax. A lot of us feel that there's equipoise in the 60 to 75 group where we really can ask a question of a randomized study. Retrospective studies might suggest that intensive therapy is a little better, but there are now a couple of randomized studies happening saying, “Can we replace ‘7+3' in that intermediate age with aza-venetoclax?” And for younger adults similarly, we're looking to see how we apply that technology. Those are the areas where we're really trying to investigate what's optimal for patients and that's going to require randomized trials. Dr. John Sweetenham: Oh, that's great, thank you. And I'll just extend that question a little bit more, particularly with respect to the new targeted therapies. How much are they impacting the treatment of these patients in the relapse and refractory setting now? Dr. James Foran: Oh, they're definitely impacting it. When I trained and probably when you trained, AML was still a medical emergency. But that was the thing that you admitted to the hospital immediately, you started therapy immediately. The rule was always that's the one thing that brings the fellow and the consultant in at night to see that new patient on a Friday or Saturday. Now, we'll still admit a patient for monitoring, but we try not to start therapy for the first three or five or seven days if they're stable, until we get those genetics and those genomics back, because it helps us discriminate what therapy to pursue. And certainly, with FLT3 mutations, especially FLT3/ITD mutations, we're adding FLT3 inhibitors and we're seeing a survival advantage. Now, on the surface, that survival advantage is in the range of 7% or 10%. But if you then pursue an allogeneic transplant in first remission, you're taking disease where we used to see 30%, 40% long-term survival, maybe less, and you're pushing that to 60%, 70% in some studies. And so we're now taking a disease that– I don't want to get off topic and talk about Ph+ ALL. But that's a disease where we're actually a little excited. We have a target now, and it used to be something really adverse and now we can do a lot for it and a lot about it.  The other mutations, it's a little more subtle. Now, who knew until 2010 that a mutation in a sugar metabolism gene, in isocitrate dehydrogenase, or IDH was going to be so important, or even that it existed. We know that IDH1 and IDH2 mutations are still a minority of AML, certainly less than 10% to 15%, maybe overall. But we're able to target those with specific IDH1 and IDH2 inhibitors. We get single-agent responses. There are now two approved IDH1 inhibitors on the market. We don't yet have the randomized data that adding those to intensive therapy is better, but we're getting a very strong hint that it might be better in older adults who have an IDH mutation, maybe adding those is helpful and maybe adding those to low-intensity therapy is helpful. Those studies are ongoing, and we're also trying with low-intensity treatments to add these agents and get higher remission rates, deeper remissions, longer remissions. I think a lot of work has to be done to delineate the safety of that and the long-term efficacy. But we're getting hints it's better, so I think it is impacting.  The other area it's impacting is when you pick up adverse mutations and those have crept into our classification systems like an ASXL1 mutation or RUNX1 mutation for instance, or some of the secondary AML mutations like BCOR and others, where that's helping us discriminate intermediate-risk patients who we think aren't going to do as well and really helping us select a group who's more likely to get benefit from allogeneic transplant or for whom at least our cure rates without allo transplant are low. And so I think it's impacting a lot. Dr. John Sweetenham: Great. And I'm going to pick up now, if I may, on a couple of things that you've just mentioned and continue the theme of the relapsed and refractory setting. We've started to see some reports which have looked at the role of immune strategies for patients with AML, in particular CAR T or NK cells. Can you comment a little on this and let us know whether you think either these two strategies or other immune strategies are likely to have a significant role in AML in the future? Dr. James Foran: They are, but I think we're still a step behind finding the right target or the right way to do it. If you think of allogeneic transplantation as the definitive immune therapy, and we know for adverse AML we can improve survival rates and cure rates with an allotransplant, then we know inherently that immune therapy matters. And so how do we do what they've done in large cell lymphoma or in CD19 targeting for B cell malignancies? How do we bring that to acute myeloid leukemia? There have been a number of efforts. There have been at least 50 trials looking at different targets. CD33, CD123, CD7, others, CLL-1. So, there have been a number of different trials looking at how to bind a CAR T or a CAR T construct that can be active. And we have hints of efficacy. There was kind of a provocative paper in the New England Journal of Medicine a year ago in April of last year from a Chinese group that looked at a CD7-based CAR T and it was 10 patients, but they used CD7 positive acute leukemia, AML or ALL and had a CD7-targeted CAR T and they actually incorporated that with a haploidentical transplant and they had really high remission rates. People tolerated it quite well. It was provocative. It hasn't yet been reproduced on a larger scale, but the strong hints that the strategy is going to work.  Now, CD33 is a little tricky to have a CAR T when CD33 is expressed on normal hematopoietic cells. CD123 likewise. That's been something where there's, I think, still promise, but we've struggled to find the trials that make that work. Right now, there's a lot of interest in leveraging NK cells and looking, for a couple of reasons, but NK cells are attractive and NK cell markers might be attractive targets. NK cells might have similar degrees of immune efficacy. It's speculative, but they are likely to have less cytokine release syndrome and less neurotoxicity than you see with CAR T. And so it's kind of attractive to leverage that. We have had some ongoing trials looking at it with bispecifics and there certainly are trials looking at it with CAR NK-based strategies. One of the antigens that people looked at is the NK group 2D. NK group 2D or NKG2D is overexpressed in AML and its ligands overexpressed. And so that's a particular potential target. So, John, it's happening and we're looking for the hints of efficacy that could then drive a pivotal trial to get something approved.  One of the other areas is not restricting yourself just to a single antigen. For instance, there is a compound that's looking at a multi-tumor-associated antigen-specific T-cell therapy, looking at multiple antigens in AML that could be overexpressed. And there were some hints of activity and efficacy and actually a new trial looking at a so-called multi-tumor associated antigen-specific T cell therapy. So without getting into specific conflicts of interest or trials, I do think that's an exciting area and an evolving area, but still an investigational area. I'll stop there and say that we're excited about it. A lot of work's going there, but I'm not quite sure which direction the field's going to pivot to there. I think that's going to take us some time to sort out. Dr. John Sweetenham: Yeah, absolutely. But as you say, exciting area and I guess continue to watch this space for now.  So you've mentioned allogeneic stem cell transplants two or three times during this discussion. Recognizing that we don't have an imatinib for AML, which has kind of pushed transplant a long way further back in the treatment algorithm, can you comment a little on, you know, whether you think the role of stem cell transplantation is changing in AML or whether it remains pretty much as it was maybe 10 years ago? Dr. James Foran: By the way, I love that you use imatinib as an introduction because that was 6 TKIs ago, and it tells you the evolution in CML and you know, now we're looking at myristoyl pocket as a target, and so on. That's a great way to sort of show you the evolution of the field.  Allogeneic transplant, it remains a core treatment for AML, and I think we're getting much smarter and much better about learning how to use it. And I'm just going to introduce the topic of measurable residual disease to tell you about that. So I am a little bit of a believer. Part of my job is I support our allogeneic transplant program, although my focus is acute myeloid leukemia, and I've trained in transplant and done it for years and did a transplant fellowship and all that. I'm much more interested in finding people who don't need a transplant than people who do. So I'm sort of looking for where can we move away from it. But it still has a core role. I'll sidestep and tell you there was an MDS trial that looked at intermediate or high-risk MDS and the role of allogeneic transplant that shows that you about double your survival. It was a BMT CTN trial published several years ago that showed you about double your three-year survival if you can find a donor within three months and get to a transplant within six months. And so it just tells you the value of allotransplant and myeloid malignancy in general. In AML we continue to use it for adverse risk disease – TP53 is its own category, I can talk about that separately – but adverse risk AML otherwise, or for patients who don't achieve a really good remission. And I still teach our fellows that an allotransplant decreases your risk of relapse by about 50%. That's still true, but you have to have a group of patients who are at high enough risk of relapse to merit the non-relapse mortality and the chronic graft versus host disease that comes with it. Now, our outcomes with transplant are better because we're better at preventing graft versus host disease with the newer strategies such as post-transplant cyclophosphamide. There are now new FDA-approved drugs for acute and chronic graft versus host disease, ruxolitinib, belumosudil, axatilimab now. So we have better ways of treating it, but we still want to be discriminating about who should get it.  And it's not just a single-minded one-size-fits-all. We learned from the MORPHO study that was published in the JCO last year that if you have FLIT3-positive AML, FLIT3/IDT-positive AML, where we would have said from retrospective studies that your post-transplant survival is 60% give or take, as opposed to 15% or 20% without it, that we can discriminate who should or shouldn't get a transplant. Now that trial was a little bit nuanced because it did not meet its primary endpoint, but it had an embedded randomization based upon MRD status and they used a very sensitive test of measurable residual disease. They used a commercial assay by Invivoscribe that could look at the presence of a FLT3/ITD in the level of 10 to the minus 5th or 10 to the minus 6th. And if you were MRD-negative and you went through a transplant, you didn't seem to get an advantage versus not. That was of maintenance with gilteritinib, I'll just sort of put that on there. But it's telling us more about who should get a transplant and who shouldn't and who should get maintenance after transplant and who shouldn't.  A really compelling study a year ago from I don't know what to call the British group now, we used to call them the MRC and then the NCRI. I'm not quite sure what to call their studies at the moment. But Dr. Jad Othman did a retrospective study a year ago that looked at patients who had NPM1 mutation, the most common mutation AML, and looked to see if you were MRD positive or MRD negative, what the impact of a transplant was. And if you're MRD negative there was not an advantage of a transplant, whereas if you're MRD positive there was. And when they stratified that by having a FLT3 mutation that cracked. If you had a FLT3 mutation at diagnosis but your NPM1 was negative in remission, it was hard to show an advantage of a transplant. So I think we're getting much more discriminating about who should or should not get a transplant by MRD testing for NPM1 and that includes the patients who have a concomitant FLT3 mutation. And we're really trying to learn more and more. Do we really need to be doing transplants in those who are MRD-negative? If you have adverse risk genetics and you're MRD-negative, I'll really need good data to tell me not to do a transplant, but I suspect bit by bit, we'll get that data. And we're looking to see if that's really the case there, too. So measurable residual disease testing is helping us discriminate, but there is still a core role of allogeneic transplant. And to reassure you, compared to, I think your allotransplant days were some time ago if I'm right. Dr. John Sweetenham: Yes. Dr. James Foran: Yeah. Well, compared to when you were doing transplants, they're better now and better for patients now. And we get people through graft versus host disease better, and we prevent it better. Dr. John Sweetenham: That's a great answer, James. Thanks for that. It really does help to put it in context, and I think it also leads us on very nicely into what's going to be my final question for you today and perhaps the trickiest, in a way. I think that everything you've told us today really emphasizes the fact that the complexity of AML treatment has increased, primarily because of an improved understanding of the molecular landscape of the disease. And it's a complicated area now. So do you have any thoughts on what type of clinical environment patients with AML should be evaluated and treated in in 2025? Dr. James Foran: Yeah, I want to give you a kind of a cautious answer to that because, you know, I'm a leukemia doctor. I work at a leukemia center and it's what we focus on. And we really pride ourselves on our outcomes and our diagnostics and our clinical trials and so on. I am very aware that the very best oncologists in America work in private practice and work in community practice or in networks, not necessarily at an academic site. And I also know they have a much harder job than I have. They have to know lung cancer, which is molecularly as complicated now as leukemia, and they have to know about breast cancer and things that I don't even know how to spell anymore. So it's not a question of competence or knowledge. It's a question of infrastructure. I'll also put a little caveat saying that I have been taught by Rich Stone at Dana-Farber, where I did a fellowship a long time ago, and believe Rich is right, that I see different patients than the community oncologists see with AML, they're seeing different people. But with that caveat, I think the first thing is you really want to make sure you've got access to excellence, specialized hematopathology, that you can get expedited cytogenetics and NGS testing results back. There was a new drug, approved just a few months ago, actually, for relapsed AML with a KMT2A rearrangement, revumenib. We didn't talk about the menin inhibitors. I'll mention them in just a second. That's a huge area of expansion and growth for us. But they're not found on NGS platforms. And normal cytogenetics might miss a KMT2A-rearrangement. And we're actually going back to FISH panels, believe it or not, on AML, to try to identify who has a KMT2A-rearrangement. And so you really want to make sure you can access the diagnostic platforms for that.  I think the National Referral Labs do an excellent job. Not always a really fast job, but an excellent job. At my institution, I get NGS results back within three days or four days. We just have an expedited platform. Not everybody has that. So that's the key, is you have to be able to make the diagnosis, trust the pathologist, get expedited results. And then it's the question of trying to access the targeted medications because a lot of them are not carried in hospital on formulary or take time to go through an insurance approval process. So that's its own little headache, getting venetoclax, getting gilteritinib, getting an IDH1 inhibitor in first line, if that's what you're going for. And so I think that requires some infrastructure. We have case managers and nurses who really expedite that and help us with it, but that's a lot of work. The other piece of the puzzle is that we're still with AML in the first month and maybe even the second month. We make everybody worse before we make them better. And you have to have really good blood bank support. I can give an outpatient platelet transfusion or red cell transfusion seven days a week. We're just built for that. That's harder to do if you're in a community hospital and you have to be collaborating with a local blood bank. And that's not always dead easy for somebody in practice. So with those caveats, I do find that my colleagues in community practice do a really good job making the diagnosis, starting people on therapy, asking for help. I think the real thing is to be able to have a regional leukemia center that you can collaborate with, connect with, text, call to make sure that you're finding the right patients who need the next level of diagnostics, clinical trial, transplant consults, to really get the best results.  There was some data at ASH a couple of years ago that looked at – the American Society of Hematology and ASCOs had similar reports – that looked at how do we do in academic centers versus community practice for keeping people on therapy. And on average, people were more likely to get six cycles of therapy instead of three cycles of therapy with azacitidine venetoclax at an academic center. Now, maybe it's different patients and maybe they had different cytogenetics and so on, but I think you have to be patient, I think you have to collaborate. But you can treat those patients in the community as long as you've got the infrastructure in place. And we've learned with virtual medicine, with Zoom and other platforms that we can deliver virtual care more effectively with the pandemic and beyond. So I think we're trying to offer virtual consults or virtual support for patients so they can stay in their home, stay in their community, stay with their oncologists, but still get access to excellent diagnostics and supportive care and transplant consults, and so on. I hope that's a reasonable answer to that question. It's a bit of a nuanced answer, which is, I think there's an important role of a leukemia center, and I think there's a really fundamental role of keeping somebody in the community they live in, and how we collaborate is the key to that. And we've spent a lot of time and effort working with the oncologists in our community to try to accomplish that.  John, I want to say two other things. I didn't mention in the molecular platforms that NPM1 mutations, we can now target those on clinical trials with menin inhibitors. We know that NPM1 signals through the Hoxa9/Meis1 pathway. We know that similar pathways are important in KMT2A rearrangements. We know that there are some other rare leukemias like those with NUP98 rearrangement. We can target those with menin inhibitors. The first menin inhibitor, revuminib, was approved by the FDA for KMT2A. We have others going to the FDA later this year for NPM1. There are now pivotal trials and advanced expanded phase 1/2 studies that are showing 30% response rates. And we're looking to see can we add those into the first-line therapy. So, we're finding more targets.  I'll say one last thing about molecular medicine. I know I'm a little off topic here, but I always told patients that getting AML was kind of like being struck by lightning. It's not something you did. Now, obviously, there are risk factors for AML, smoking or obesity or certain farm environments, or radioactive exposures and so on. But bit by bit, we're starting to learn about who's predisposed to AML genetically. We've identified really just in the last five or eight years that DDX41 mutations can be germline half the time. And you always think germline mutations are going to cause AML in a younger patient, but the median age is 60 to 70 just like other AMLs. They actually might do pretty well once they get AML. We've reported that in several papers. And so we're trying to understand who that has a RUNX1 mutation needs germline testing, who with a DDX41 needs germline testing. And we're trying to actually come up with a cleaner pathway for germline testing in patients to really understand predisposition, to help with donor selection, to help with family counseling. So I think those are other areas where a leukemia center can contribute for somebody in who's community practice to understand genomic or genetic complexity in these patients. And we're starting to develop the databases that support that. Dr. John Sweetenham: Yeah, great. Thanks, James. I loved your answer about the clinical environment too. And I know from a patient-centric perspective that I know that patients would certainly appreciate the fact that we're in a situation now where the folks taking care of them will make every effort to keep them close to home if they possibly can.  I want to thank you, James, for an incredible review of a very complex subject and I think you did a great job. I think we all will have learned a lot. And thanks again for being willing to share your insights with us today on the ASCO Daily News Podcast. Dr. James Foran: John, it's my pleasure. And as you know, I'll do anything for a latte, so no problem at all. Dr. John Sweetenham: Okay. I owe you one, so thank you for that.  And thank you to our listeners for your time today. You'll find links to the studies we've discussed today in the transcript of this episode. And finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:  Dr. John Sweetenham  Dr. James Foran Follow ASCO on social media: @ASCO on Twitter ASCO on Bluesky ASCO on Facebook  ASCO on LinkedIn  Disclosures:    Dr. John Sweetenham:    No relationships to disclose Dr. James Foran: Stock and Other Ownership Interests: Aurinia Pharmaceuticals Consulting or Advisory Role: Peerview, CTI BioPharma Corp, Remix Therapeutics, Cardinal Health, Medscape, Syndax, Autolus Therapeutics Research Funding (Inst.): Chordia Therapeutics, Abbvie, Actinium Pharmaceuticals, Kura Oncology, Sellas Life Sciences, Novartis, Roivant, Celgene/Bristol-Myers Squibb, Astellas Pharma, SERVIER Travel, Accommodations, Expenses: Peerview

In this episode, Dr Elle Wadsworth talks to Dr Noa Krawczyk from the Department of Population Health at NYU Grossman School of Medicine about her and her co-authors research report on self-reported experiences and perspectives on using psychedelics to manage opioid use among participants of two Reddit communities. Noa discusses the current treatments available for opioid use disorder and why psychedelics are having their moment as an alternative medicine, and what people who use opioids found when taking psychedelics with the intention of reducing or stopping their opioid use. · What is Reddit and why is Noa using it to answer her research questions [01:24]· The headline findings of the study [02:17]· The comparison of demographics of Reddit and the wider population of people who use opioids [03:46]· What the current treatments are for opioid use disorder in the US and why people are seeking alternatives [05:22]· Why Ibogaine stands out as a prominent psychedelic in the discussion [08:12]· The mechanisms of action found in the analysis [09:45]· The benefits and drawbacks of using psychedelics [13:26]· What we can take from the paper for policy and practice [15:28]About Elle Wadsworth: Elle is an academic fellow with the Society for the Study of Addiction. She is based at the University of Bath and her research interests include drug policy, cannabis legalisation, and public health. Elle is also a senior analyst at RAND Europe, working on projects focusing on national and international drug policies. About Noa Krawczyk: Noa Krawczyk, PhD, is an assistant professor in the Department of Population Health at NYU Grossman School of Medicine and Associate Director of the NYU Langone Center for Opioid Epidemiology and Policy. Her research focuses on studying ways to address barriers to evidence-based treatment for opioid use disorder at the individual, program, and policy levels. Her work centers on bridging research and practice by collaborating with drug user organizations, health system leaders, public health and government agencies, and advancing science that can help inform evidence-based policies and practices that reduce harm and promote well being.About co-author Megan Miller: Megan Miller, MPH, is a Research Coordinator in the Center for Opioid Epidemiology and Policy at NYU Grossman School of Medicine and served as the primary data analyst for the Reddit study. She holds an MPH from the University of North Carolina at Chapel Hill. NK receives fees as an expert witness in ongoing opioid litigation. MM has no conflicts of interest to declare.Original article: Self-reported experiences and perspectives on using psychedelics to manage opioid use among participants of two Reddit communities https://doi.org/10.1111/add.16767 The opinions expressed in this podcast reflect the views of the host and interviewees and do not necessarily represent the opinions or official positions of the SSA or Addiction journal. The SSA does not endorse or guarantee the accuracy of the information in external sources or links and accepts no responsibility or liability for any consequences arising from the use of such information. Hosted on Acast. See acast.com/privacy for more information.

In this week's episode we'll learn more about the significance of hypercalcemia in monoclonal gammopathy of undetermined significance, the role of neutrophil gelatinase-associated lipocalin in hemostasis, and the feasibility of combining CD19-targeted NK- or T-cell therapy with anti-CD19 monoclonal antibodies.Featured Articles:Approaching Hypercalcemia in Gammopathy of Undetermined Significance: Insights from the iStopMM study Deficiency of neutrophil gelatinase-associated lipocalin elicits Hemophilia-like bleeding and clotting disorder Anti-CD19 antibody cotreatment enhances serial killing activity of anti-CD19 CAR-T/-NK cells and reduces trogocytosis 

47e6GvjL4in5Zy5vVHMb9PQtGXQAcFvWSCQn2fuwDYZoZRk3oFjefr51WBNDGG9EjF1YDavg7pwGDFSAVWC5K42CBcLLv5U OR DONATE HERE: https://www.monerotalk.live/donate LINKS: TIMESTAMPS (00:00:00) Monerotopia Introduction. (00:02:28) Monerotopia Price Report Segment w/ Bawdyanarchist. (01:06:25) Monerotopia News Segment w/ Tony. (01:11:10) Peter Schiff monero pilled? (01:16:27) Monero mentioned in a Turkish movie. (01:17:45) Monero back on CEXs? No (01:25:52) NK owns the most ETH (01:26:35) Bybit hack. (01:27:55) Apple surrenders in the UK (01:31:58) SEC withdraws its appeal over Defi (01:32:25) Quantum breakthroughs (01:34:44) Lightning network things (01:35:22) Fort Knox live (01:37:35) Jack Dorsey is Satoshi? (01:41:20) Zcash anthem (01:44:10) Monerotopia Viewers on Stage Segment. (02:33:40) Monerotopia Finalization. NEWS SEGMENT LINKS: Monero mentioned in a Turkish movie: https://x.com/undetectedtx/status/1891183354650734824?s=46&t=mVZ0A2C1bwwnAvgawJjlw Jack Dorsey is Satoshi?: https://x.com/matthewsigel/status/1891852538376487327?s=46&t=mVZ0A2C1bwwnAvgawJjlw Peter Schiff monero pilled?: https://x.com/moneromavrick/status/1891909236382118386?s=46&t=mVZ0A2C1bwwnAvgawJjlw Zcash anthem: https://x.com/allismadenew/status/1892040995505578167?s=46&t=mVZ0A2C1bwwnAvgawJjlw Lightning network things: https://x.com/cryptonator1337/status/1892139131213697448?s=46&t=mVZ0A2C1bwwnAvgawJjlw Quantum breakthroughs: https://x.com/satyanadella/status/1892242895094313420?s=46&t=mVZ0A2C1bwwnAvgawJjlw SEC withdraws its appeal over Defi: https://x.com/cointelegraph/status/1892454136567730467?s=46&t=mVZ0A2C1bwwnAvgawJjlw Apple surrenders in the UK: https://x.com/inevitablewest/status/1892959668458156298?s=46 Fort Knox live: https://x.com/elonmusk/status/1892779555548443116?s=46&t=mVZ0A2C1bwwnAvgawJjlw NK owns the most ETH: https://x.com/0xwenmoon/status/1893161253985481000?s=46&t=mVZ0A2C1bwwnAvgawJjlw Monero back on CEXs? No: https://www.reddit.com/r/Monero/s/8BZjsjrkVx SPONSORS: PRICE REPORT: https://exolix.com/ GUEST SEGMENT: https://cakewallet.com & https://monero.com NEWS SEGMENT: https://www.wizardswap.io Don't forget to SUBSCRIBE! The more subscribers, the more we can help Monero grow! XMRtopia TELEGRAM: https://t.me/monerotopia XMRtopia MATRIX: https://matrix.to/#/%23monerotopia%3Amonero.social ODYSEE: https://bit.ly/3bMaFtE WEBSITE: monerotopia.com CONTACT: monerotopia@protonmail.com MASTADON: @Monerotopia@mastodon.social MONERO.TOWN https://monero.town/u/monerotopia Get Social with us: X: https://twitter.com/monerotopia INSTAGRAM: https://www.instagram.com/monerotopia DOUGLAS: https://twitter.com/douglastuman SUNITA: https://twitter.com/sunchakr TUX: https://twitter.com/tuxpizza

RKC-spits Michiel Kramer, ESPN-presentator Sanne van Dongen en oud-atleet Gregory Sedoc zijn te gast.  Er wordt gesproken over de sensationele prestaties van de Nederlandse voetbalclubs in Europa, het NK atletiek en de Oranjevrouwen, waar Sherida Spitse haar aanvoerdersband dreigt kwijt te raken. 

Canadian journalist Nora Loreto reads the latest headlines for Thursday, February 6, 2025.TRNN has partnered with Loreto to syndicate and share her daily news digest with our audience. Tune in every morning to the TRNN podcast feed to hear the latest important news stories from Canada and worldwide.Find more headlines from Nora at Sandy & Nora Talk Politics podcast feed.Help us continue producing radically independent news and in-depth analysis by following us and becoming a monthly sustainer.Sign up for our newsletterLike us on FacebookFollow us on TwitterDonate to support this podcast

In deze aflevering van Barre Beukers bespreken Shady, Zhe-man en Gerwin de wedstrijden van de Weissensee, waaronder de AKM en het NK. Ze bespreken de prestaties van verschillende schaatsers, de tactieken tijdens de wedstrijden, en de organisatorische beslissingen rondom de 200km. Verder wordt er gespeculeerd over transfers binnen schaatsploegen en de kansen van Nederlandse schaatsers op de Olympische Spelen. Tot slot raken ze ook nog het onderwerp bingo aan.

Mimoriadna inventúra všetkých kľúčových inštitúcií štátu, ale najmä Katastra nehnuteľností. To je odporúčanie šéfa NKÚ v exkluzívnom rozhovore pre Ráno Nahlas. Podľa neho po hekerskom útoku nemáme istotu, že nedošlo k posunom na listoch vlastníctva. Prípad odhalil zásadné rezervy v kybernetickej bezpečnosti Slovenska, ako i masívne mrhanie financií v oblasti informatizácie, tvrdí Ľubomír Andrassy. A prečo si štát nenajme služby firmy Eset?Kataster nehnuteľností čelil masívnemu útoku neznámych hekerov. Útok, ktorý Katastrálny úrad doslova paralyzoval, tak v plnej sile odhalil slabiny v oblasti kybernetickej bezpečnosti kritickej infraštruktúry nášho štátu."Ak celý projekt vznikal v roku 2007 a mal byť spustený do prevádzky v roku 2012, tak my sme sa pozreli na tento projekt v roku 2019. Vtedy sme skonštatovali, že ani 7 rokov po tom ako projekt mal slúžiť občanom i štátnym inštitúciám, tak nič v tom čase nefungovalo. Čo je však ešte horšie, štátne úrady, ktoré za tento projekt zodpovedali, verejnosť - i Brusel (ktorý to platil) zavádzali a tvrdili, že všetko funguje, čo ale vôbec nebola pravda." Tvrdí šéf NKÚ pre Aktuality. Do informatizácie Slovenska pritom Európska únia naliala už niekoľko miliárd eur, výsledky v podobe moderného digitálneho štátu na úrovni 21. storočia sú však až neuveriteľne žalostné. Natíska sa preto logická otázka: Kam všetky tieto peniaze vlastne išli, kto z nich mal skutočný profit a prečo je stav digitalizácie - ale i kybernetickej bezpečnosti tohto štátu, na tak chabej úrovni?Na premrhané financie v oblasti informatizácie pritom dlhodobo upozorňuje aj Najvyšší kontrolný úrad. Ten ale aktuálne čelí čoraz častejším a ostrejším útokom. Dôvodom sú zistenia jeho kontrolórov voči ktorým sa kontrolované subjekty bránia šikanou či dokonca zastrašovaním. Namiesto nápravy odhalených nedostatkov si za verejné zdroje najímajú právnikov, ktorí sa snažia kontrolu nielen sťažiť, ale dokonca chcú utajiť jej výsledky pred verejnosťou, hovorí pre Aktuality šéf NKÚ Ľubomír Andrassy."Ak sa budú v dôležitých štátnych funkciách objavovať ľudia ako Majka z Gurunu na Štrbskom plese a ak budeme do pozícií v rámci kľúčových inštitúcií štátu pre riadenie krajiny v mimoriadnych situáciách dosadzovať ľudí nie na základe odbornosti, ale na základe ich kamarátstva s politikmi, tak schopnosť štátu reagovať na výzvy doby bude čoraz komplikovanejšia a občania si budú čoraz viac klásť otázku, či je Slovenská republika vedená ľuďmi, ktorí vôbec tušia, kam ju chcú doviesť a majú aspoň nejakú predstavu, ako má fungovať moderná demokratická krajina." odkazuje verejnosti šéf štátnych kontrolórov. Vzhľadom na závažnosť zistení NKÚ, ich celospoločenský dosah, opakovanú relevantnosť, ale rovnako tak i rastúcu mieru tlaku na NKÚ, sme sa v Aktualitách rozhodli poskytnúť šéfovi Najvyššieho kontrolného úradu pravidelný priestor na zistenia kontrolórov NKÚ.Počúvate Ráno Nahlas, pekný deň a pokoj v duši praje Braňo Dobšinský.

On this episode, we talk about The Tale Of The Long Ago Lockethttps://www.facebook.com/hashtag/anthology?__eep__=6&__cft__[0]=AZUB7KsGvVEJuJHThl0JWi1E7N2IYqmvNIhPxVdkyqfGleLQHYAovZs8kRPMGWUO6BT4Hs2GRP8E_Ekhah6Ot5Zrj1HHd1pF05F1KtPR6DeVJwvxcevCt659XFmBKh_K06HWXSYIOk0DS9qG7Z6vc1S0x0_MueV0LRzIPeMO844RbFTWo3me3qToSmPuNh8O3d3mVM_Miu9ZirXxnsftzC2Uf9pwnzTO8la5mmg2EeZbwg&__tn__=*NK-y-R https://www.facebook.com/hashtag/horror?__eep__=6&__cft__[0]=AZUB7KsGvVEJuJHThl0JWi1E7N2IYqmvNIhPxVdkyqfGleLQHYAovZs8kRPMGWUO6BT4Hs2GRP8E_Ekhah6Ot5Zrj1HHd1pF05F1KtPR6DeVJwvxcevCt659XFmBKh_K06HWXSYIOk0DS9qG7Z6vc1S0x0_MueV0LRzIPeMO844RbFTWo3me3qToSmPuNh8O3d3mVM_Miu9ZirXxnsftzC2Uf9pwnzTO8la5mmg2EeZbwg&__tn__=*NK-y-R https://www.facebook.com/hashtag/90shorror?__eep__=6&__cft__[0]=AZUB7KsGvVEJuJHThl0JWi1E7N2IYqmvNIhPxVdkyqfGleLQHYAovZs8kRPMGWUO6BT4Hs2GRP8E_Ekhah6Ot5Zrj1HHd1pF05F1KtPR6DeVJwvxcevCt659XFmBKh_K06HWXSYIOk0DS9qG7Z6vc1S0x0_MueV0LRzIPeMO844RbFTWo3me3qToSmPuNh8O3d3mVM_Miu9ZirXxnsftzC2Uf9pwnzTO8la5mmg2EeZbwg&__tn__=*NK-y-R https://www.facebook.com/hashtag/horrorforkids?__eep__=6&__cft__[0]=AZUB7KsGvVEJuJHThl0JWi1E7N2IYqmvNIhPxVdkyqfGleLQHYAovZs8kRPMGWUO6BT4Hs2GRP8E_Ekhah6Ot5Zrj1HHd1pF05F1KtPR6DeVJwvxcevCt659XFmBKh_K06HWXSYIOk0DS9qG7Z6vc1S0x0_MueV0LRzIPeMO844RbFTWo3me3qToSmPuNh8O3d3mVM_Miu9ZirXxnsftzC2Uf9pwnzTO8la5mmg2EeZbwg&__tn__=*NK-y-R https://www.facebook.com/hashtag/ayaotd?__eep__=6&__cft__[0]=AZUB7KsGvVEJuJHThl0JWi1E7N2IYqmvNIhPxVdkyqfGleLQHYAovZs8kRPMGWUO6BT4Hs2GRP8E_Ekhah6Ot5Zrj1HHd1pF05F1KtPR6DeVJwvxcevCt659XFmBKh_K06HWXSYIOk0DS9qG7Z6vc1S0x0_MueV0LRzIPeMO844RbFTWo3me3qToSmPuNh8O3d3mVM_Miu9ZirXxnsftzC2Uf9pwnzTO8la5mmg2EeZbwg&__tn__=*NK-y-R https://www.facebook.com/hashtag/areyouafraidofthedark?__eep__=6&__cft__[0]=AZUB7KsGvVEJuJHThl0JWi1E7N2IYqmvNIhPxVdkyqfGleLQHYAovZs8kRPMGWUO6BT4Hs2GRP8E_Ekhah6Ot5Zrj1HHd1pF05F1KtPR6DeVJwvxcevCt659XFmBKh_K06HWXSYIOk0DS9qG7Z6vc1S0x0_MueV0LRzIPeMO844RbFTWo3me3qToSmPuNh8O3d3mVM_Miu9ZirXxnsftzC2Uf9pwnzTO8la5mmg2EeZbwg&__tn__=*NK-y-R https://www.facebook.com/hashtag/jasonalisharan?__eep__=6&__cft__[0]=AZUB7KsGvVEJuJHThl0JWi1E7N2IYqmvNIhPxVdkyqfGleLQHYAovZs8kRPMGWUO6BT4Hs2GRP8E_Ekhah6Ot5Zrj1HHd1pF05F1KtPR6DeVJwvxcevCt659XFmBKh_K06HWXSYIOk0DS9qG7Z6vc1S0x0_MueV0LRzIPeMO844RbFTWo3me3qToSmPuNh8O3d3mVM_Miu9ZirXxnsftzC2Uf9pwnzTO8la5mmg2EeZbwg&__tn__=*NK-y-R https://www.facebook.com/hashtag/nathanielmoreau?__eep__=6&__cft__[0]=AZUB7KsGvVEJuJHThl0JWi1E7N2IYqmvNIhPxVdkyqfGleLQHYAovZs8kRPMGWUO6BT4Hs2GRP8E_Ekhah6Ot5Zrj1HHd1pF05F1KtPR6DeVJwvxcevCt659XFmBKh_K06HWXSYIOk0DS9qG7Z6vc1S0x0_MueV0LRzIPeMO844RbFTWo3me3qToSmPuNh8O3d3mVM_Miu9ZirXxnsftzC2Uf9pwnzTO8la5mmg2EeZbwg&__tn__=*NK-y-R https://www.facebook.com/hashtag/rachelblanchard?__eep__=6&__cft__[0]=AZUB7KsGvVEJuJHThl0JWi1E7N2IYqmvNIhPxVdkyqfGleLQHYAovZs8kRPMGWUO6BT4Hs2GRP8E_Ekhah6Ot5Zrj1HHd1pF05F1KtPR6DeVJwvxcevCt659XFmBKh_K06HWXSYIOk0DS9qG7Z6vc1S0x0_MueV0LRzIPeMO844RbFTWo3me3qToSmPuNh8O3d3mVM_Miu9ZirXxnsftzC2Uf9pwnzTO8la5mmg2EeZbwg&__tn__=*NK-y-R https://www.facebook.com/hashtag/rosshull?__eep__=6&__cft__[0]=AZUB7KsGvVEJuJHThl0JWi1E7N2IYqmvNIhPxVdkyqfGleLQHYAovZs8kRPMGWUO6BT4Hs2GRP8E_Ekhah6Ot5Zrj1HHd1pF05F1KtPR6DeVJwvxcevCt659XFmBKh_K06HWXSYIOk0DS9qG7Z6vc1S0x0_MueV0LRzIPeMO844RbFTWo3me3qToSmPuNh8O3d3mVM_Miu9ZirXxnsftzC2Uf9pwnzTO8la5mmg2EeZbwg&__tn__=*NK-y-Rhttps://www.facebook.com/hashtag/raineparecoull?__eep__=6&__cft__[0]=AZUB7KsGvVEJuJHThl0JWi1E7N2IYqmvNIhPxVdkyqfGleLQHYAovZs8kRPMGWUO6BT4Hs2GRP8E_Ekhah6Ot5Zrj1HHd1pF05F1KtPR6DeVJwvxcevCt659XFmBKh_K06HWXSYIOk0DS9qG7Z6vc1S0x0_MueV0LRzIPeMO844RbFTWo3me3qToSmPuNh8O3d3mVM_Miu9ZirXxnsftzC2Uf9pwnzTO8la5mmg2EeZbwg&__tn__=*NK-y-R https://www.facebook.com/hashtag/jodieresther?__eep__=6&__cft__[0]=AZUB7KsGvVEJuJHThl0JWi1E7N2IYqmvNIhPxVdkyqfGleLQHYAovZs8kRPMGWUO6BT4Hs2GRP8E_Ekhah6Ot5Zrj1HHd1pF05F1KtPR6DeVJwvxcevCt659XFmBKh_K06HWXSYIOk0DS9qG7Z6vc1S0x0_MueV0LRzIPeMO844RbFTWo3me3qToSmPuNh8O3d3mVM_Miu9ZirXxnsftzC2Uf9pwnzTO8la5mmg2EeZbwg&__tn__=*NK-y-R https://www.facebook.com/hashtag/jacobtierney?__eep__=6&__cft__[0]=AZUB7KsGvVEJuJHThl0JWi1E7N2IYqmvNIhPxVdkyqfGleLQHYAovZs8kRPMGWUO6BT4Hs2GRP8E_Ekhah6Ot5Zrj1HHd1pF05F1KtPR6DeVJwvxcevCt659XFmBKh_K06HWXSYIOk0DS9qG7Z6vc1S0x0_MueV0LRzIPeMO844RbFTWo3me3qToSmPuNh8O3d3mVM_Miu9ZirXxnsftzC2Uf9pwnzTO8la5mmg2EeZbwg&__tn__=*NK-y-R https://www.facebook.com/hashtag/djmachale?__eep__=6&__cft__[0]=AZUB7KsGvVEJuJHThl0JWi1E7N2IYqmvNIhPxVdkyqfGleLQHYAovZs8kRPMGWUO6BT4Hs2GRP8E_Ekhah6Ot5Zrj1HHd1pF05F1KtPR6DeVJwvxcevCt659XFmBKh_K06HWXSYIOk0DS9qG7Z6vc1S0x0_MueV0LRzIPeMO844RbFTWo3me3qToSmPuNh8O3d3mVM_Miu9ZirXxnsftzC2Uf9pwnzTO8la5mmg2EeZbwg&__tn__=*NK-y-R https://www.facebook.com/hashtag/nedkandel?__eep__=6&__cft__[0]=AZUB7KsGvVEJuJHThl0JWi1E7N2IYqmvNIhPxVdkyqfGleLQHYAovZs8kRPMGWUO6BT4Hs2GRP8E_Ekhah6Ot5Zrj1HHd1pF05F1KtPR6DeVJwvxcevCt659XFmBKh_K06HWXSYIOk0DS9qG7Z6vc1S0x0_MueV0LRzIPeMO844RbFTWo3me3qToSmPuNh8O3d3mVM_Miu9ZirXxnsftzC2Uf9pwnzTO8la5mmg2EeZbwg&__tn__=*NK-y-R https://www.facebook.com/hashtag/cinar?__eep__=6&__cft__[0]=AZUB7KsGvVEJuJHThl0JWi1E7N2IYqmvNIhPxVdkyqfGleLQHYAovZs8kRPMGWUO6BT4Hs2GRP8E_Ekhah6Ot5Zrj1HHd1pF05F1KtPR6DeVJwvxcevCt659XFmBKh_K06HWXSYIOk0DS9qG7Z6vc1S0x0_MueV0LRzIPeMO844RbFTWo3me3qToSmPuNh8O3d3mVM_Miu9ZirXxnsftzC2Uf9pwnzTO8la5mmg2EeZbwg&__tn__=*NK-y-R https://www.facebook.com/hashtag/nickelodeon?__eep__=6&__cft__[0]=AZUB7KsGvVEJuJHThl0JWi1E7N2IYqmvNIhPxVdkyqfGleLQHYAovZs8kRPMGWUO6BT4Hs2GRP8E_Ekhah6Ot5Zrj1HHd1pF05F1KtPR6DeVJwvxcevCt659XFmBKh_K06HWXSYIOk0DS9qG7Z6vc1S0x0_MueV0LRzIPeMO844RbFTWo3me3qToSmPuNh8O3d3mVM_Miu9ZirXxnsftzC2Uf9pwnzTO8la5mmg2EeZbwg&__tn__=*NK-y-RCheck out:http://talesfromthepodcast.com/?fbclid=IwZXh0bgNhZW0CMTAAAR01ahw1xE6tqWBii3PQNX9tWKhMLchmaEnhzS1GYzxAnDORuEUBYtOfi5c_aem_WZ5_Z8zc8MSQJvv6CmDuTghttp://linktr.ee/skewereduniversepodcast?fbclid=IwZXh0bgNhZW0CMTAAAR2K9TLdo6k5Qr_VqWFYi2K8TqjG_fRi1qs5HIy9_gv7ggcoBfCXY549ous_aem_AcmowOpgmw2-GT1Aw9V1LQhttp://happyhournewsteam.com/?fbclid=IwZXh0bgNhZW0CMTAAAR0p1wlWohIXB_96DhrdoD62x-9l8VT2L7TF_3I8bMrTUofVXNSSXh_FjdU_aem_92TWoXHpmEsGgaPCdViYyAAnd can contact me through email here at talesfromthepodcast13@gmail.WooHoo!!!Tales From The Podcast The Fucking Video Game out now for PC!Purchase now for $10Send payment and email to:PayPal - talesfromthepodcast13@gmail.comCashApp - $talesfromthepodcast$5 more and you pansies get a cheatbot!https://www.facebook.com/hashtag/horror?__eep__=6&__cft__[0]=AZUB7KsGvVEJuJHThl0JWi1E7N2IYqmvNIhPxVdkyqfGleLQHYAovZs8kRPMGWUO6BT4Hs2GRP8E_Ekhah6Ot5Zrj1HHd1pF05F1KtPR6DeVJwvxcevCt659XFmBKh_K06HWXSYIOk0DS9qG7Z6vc1S0x0_MueV0LRzIPeMO844RbFTWo3me3qToSmPuNh8O3d3mVM_Miu9ZirXxnsftzC2Uf9pwnzTO8la5mmg2EeZbwg&__tn__=*NK-y-R https://www.facebook.com/hashtag/rpg?__eep__=6&__cft__[0]=AZUB7KsGvVEJuJHThl0JWi1E7N2IYqmvNIhPxVdkyqfGleLQHYAovZs8kRPMGWUO6BT4Hs2GRP8E_Ekhah6Ot5Zrj1HHd1pF05F1KtPR6DeVJwvxcevCt659XFmBKh_K06HWXSYIOk0DS9qG7Z6vc1S0x0_MueV0LRzIPeMO844RbFTWo3me3qToSmPuNh8O3d3mVM_Miu9ZirXxnsftzC2Uf9pwnzTO8la5mmg2EeZbwg&__tn__=*NK-y-R https://www.facebook.com/hashtag/indiegame?__eep__=6&__cft__[0]=AZUB7KsGvVEJuJHThl0JWi1E7N2IYqmvNIhPxVdkyqfGleLQHYAovZs8kRPMGWUO6BT4Hs2GRP8E_Ekhah6Ot5Zrj1HHd1pF05F1KtPR6DeVJwvxcevCt659XFmBKh_K06HWXSYIOk0DS9qG7Z6vc1S0x0_MueV0LRzIPeMO844RbFTWo3me3qToSmPuNh8O3d3mVM_Miu9ZirXxnsftzC2Uf9pwnzTO8la5mmg2EeZbwg&__tn__=*NK-y-R https://www.facebook.com/hashtag/pcgaming?__eep__=6&__cft__[0]=AZUB7KsGvVEJuJHThl0JWi1E7N2IYqmvNIhPxVdkyqfGleLQHYAovZs8kRPMGWUO6BT4Hs2GRP8E_Ekhah6Ot5Zrj1HHd1pF05F1KtPR6DeVJwvxcevCt659XFmBKh_K06HWXSYIOk0DS9qG7Z6vc1S0x0_MueV0LRzIPeMO844RbFTWo3me3qToSmPuNh8O3d3mVM_Miu9ZirXxnsftzC2Uf9pwnzTO8la5mmg2EeZbwg&__tn__=*NK-y-R https://www.facebook.com/hashtag/oldschool?__eep__=6&__cft__[0]=AZUB7KsGvVEJuJHThl0JWi1E7N2IYqmvNIhPxVdkyqfGleLQHYAovZs8kRPMGWUO6BT4Hs2GRP8E_Ekhah6Ot5Zrj1HHd1pF05F1KtPR6DeVJwvxcevCt659XFmBKh_K06HWXSYIOk0DS9qG7Z6vc1S0x0_MueV0LRzIPeMO844RbFTWo3me3qToSmPuNh8O3d3mVM_Miu9ZirXxnsftzC2Uf9pwnzTO8la5mmg2EeZbwg&__tn__=*NK-y-R https://www.facebook.com/hashtag/funny?__eep__=6&__cft__[0]=AZUB7KsGvVEJuJHThl0JWi1E7N2IYqmvNIhPxVdkyqfGleLQHYAovZs8kRPMGWUO6BT4Hs2GRP8E_Ekhah6Ot5Zrj1HHd1pF05F1KtPR6DeVJwvxcevCt659XFmBKh_K06HWXSYIOk0DS9qG7Z6vc1S0x0_MueV0LRzIPeMO844RbFTWo3me3qToSmPuNh8O3d3mVM_Miu9ZirXxnsftzC2Uf9pwnzTO8la5mmg2EeZbwg&__tn__=*NK-y-R https://www.facebook.com/hashtag/adult?__eep__=6&__cft__[0]=AZUB7KsGvVEJuJHThl0JWi1E7N2IYqmvNIhPxVdkyqfGleLQHYAovZs8kRPMGWUO6BT4Hs2GRP8E_Ekhah6Ot5Zrj1HHd1pF05F1KtPR6DeVJwvxcevCt659XFmBKh_K06HWXSYIOk0DS9qG7Z6vc1S0x0_MueV0LRzIPeMO844RbFTWo3me3qToSmPuNh8O3d3mVM_Miu9ZirXxnsftzC2Uf9pwnzTO8la5mmg2EeZbwg&__tn__=*NK-y-R https://www.facebook.com/hashtag/sexy?__eep__=6&__cft__[0]=AZUB7KsGvVEJuJHThl0JWi1E7N2IYqmvNIhPxVdkyqfGleLQHYAovZs8kRPMGWUO6BT4Hs2GRP8E_Ekhah6Ot5Zrj1HHd1pF05F1KtPR6DeVJwvxcevCt659XFmBKh_K06HWXSYIOk0DS9qG7Z6vc1S0x0_MueV0LRzIPeMO844RbFTWo3me3qToSmPuNh8O3d3mVM_Miu9ZirXxnsftzC2Uf9pwnzTO8la5mmg2EeZbwg&__tn__=*NK-y-R

We love to hear from our listeners. Send us a message.Christopher Horan, Chief Technical Operations Officer, Artiva Biotherapeutics joins Cell & Gene: The Podcast Host, Erin Harris, to discuss the advantages natural killer (NK) cells have offer over T cells in terms of safety and efficacy for autoimmune disease. They take a deep dive into the key factors that make NK cells promising for ‘off-the-shelf' cell therapy products. They cover Artiva's "manufacturing first" approach to enabling scalable NK cell production, and much more.Subscribe to the podcast!Apple | Spotify | YouTube

Just Give Me a Reason – P!NK (feat. Nate Ruess)

這次來北海道的8天，一路平安到目前為止沒有任何呼吸道感染的跡象，看來全身而退了，應該是很大機會沒有得到流感病毒。流感病毒的潛伏期約1-4天，平均為2天。所以要到回來後第4天，就解除警報啦。 給大家看看我這一趟準備的防疫小物。 1.口罩。我沒有全程戴，主要是在室內不通風或是擁擠的地方，室外很冷的時候也順便有保暖的作用，哈。濕了就會失效，要更換。 2.酒精乾洗手。小於100毫升，可帶上飛機。只要可能摸到太多人摸過的東西我就會用一下，比方說手扶梯或是電梯鈕。 3.每天一瓶明治R1優酪乳。根據明治官網，R-1乳酸菌具有增強免疫的NK細胞（自然殺手細胞）活性的效果，可降低感冒的風險。我們的免疫系統有好幾道防線，NK細胞是最先攻擊侵入身體的病原體的第一道防線之一。NK細胞會攻擊感染病毒的細胞等異常細胞並予以破壞，可說是防禦病毒的關鍵。 這篇有詳細介紹 https://linshibi.com/?p=48557 4.維生素C發泡錠一天一顆。我是在台灣好市多買的力度伸，這牌還有含鋅。這兩者科學上應該沒有非常確切可以預防流感的證據就是了。 5.噴的蜂膠。喉嚨怪怪時就噴一下。小狸趁特價時網購了很多，我們用的是澳洲HEALTH NATURE GoldenHive蜂膠滴劑。 6.感冒症狀治療藥物。你可從台灣帶，也可在日本藥妝店再買。我帶了LOXONIN複方藥物，還有喉嚨痛的口服和小河馬噴劑。你當然可以帶類似大正百保能這樣的複方藥物，或是單方的解熱鎮痛藥，比方說EVE。 大正百保能黃金A微粒 黃金A錠感冒藥 比價 日本台灣配方成分有何不同？ https://linshibi.com/?p=46969 EVE A止痛藥 頭痛生理痛有效嗎？成分 效果 副作用有何不同？ https://linshibi.com/?p=45191 7.喉糖。這款LION出的"藥日本堂"喉糖我其實沒吃過，家裡上次有買就帶著了（是有多怕喉嚨痛）。 延伸閱讀： 日本流感進入大流行期 要打流感疫苗嗎？可以和新冠疫苗一起打嗎？左流右新？ https://linshibi.com/?p=48579 旅平險海外突發疾病 請注意有無給付法定傳染病 美商安達 臺灣產物保險 旺旺友聯 南山人壽 https://linshibi.com/?p=48622

On this episode, we recap season 3!https://www.facebook.com/hashtag/anthology?__eep__=6&__cft__[0]=AZWJWQndS1sZVZGIjtAekJzP9ho_Qo1Dw560Xx5XZsGHpH4aasP5CF7-JDeHCWkQDImnxGhzOrdi8mJJH2q5q8iib5ouVTpyhVw1mq-vGn9nFC5VS1rORrdjaXyIPCjrYikLQknI_jVRnzAOlYaZUrkB2l33YXkFW2x0_R2haLn9igjRokaQ0QlzviJAMBf1DPtFZfayVEbnLU3UEQqliViwMMtwq1wvHM25IbPbYBD4XQ&__tn__=*NK-y-R https://www.facebook.com/hashtag/horror?__eep__=6&__cft__[0]=AZWJWQndS1sZVZGIjtAekJzP9ho_Qo1Dw560Xx5XZsGHpH4aasP5CF7-JDeHCWkQDImnxGhzOrdi8mJJH2q5q8iib5ouVTpyhVw1mq-vGn9nFC5VS1rORrdjaXyIPCjrYikLQknI_jVRnzAOlYaZUrkB2l33YXkFW2x0_R2haLn9igjRokaQ0QlzviJAMBf1DPtFZfayVEbnLU3UEQqliViwMMtwq1wvHM25IbPbYBD4XQ&__tn__=*NK-y-R https://www.facebook.com/hashtag/90shorror?__eep__=6&__cft__[0]=AZWJWQndS1sZVZGIjtAekJzP9ho_Qo1Dw560Xx5XZsGHpH4aasP5CF7-JDeHCWkQDImnxGhzOrdi8mJJH2q5q8iib5ouVTpyhVw1mq-vGn9nFC5VS1rORrdjaXyIPCjrYikLQknI_jVRnzAOlYaZUrkB2l33YXkFW2x0_R2haLn9igjRokaQ0QlzviJAMBf1DPtFZfayVEbnLU3UEQqliViwMMtwq1wvHM25IbPbYBD4XQ&__tn__=*NK-y-R https://www.facebook.com/hashtag/horrorforkids?__eep__=6&__cft__[0]=AZWJWQndS1sZVZGIjtAekJzP9ho_Qo1Dw560Xx5XZsGHpH4aasP5CF7-JDeHCWkQDImnxGhzOrdi8mJJH2q5q8iib5ouVTpyhVw1mq-vGn9nFC5VS1rORrdjaXyIPCjrYikLQknI_jVRnzAOlYaZUrkB2l33YXkFW2x0_R2haLn9igjRokaQ0QlzviJAMBf1DPtFZfayVEbnLU3UEQqliViwMMtwq1wvHM25IbPbYBD4XQ&__tn__=*NK-y-R https://www.facebook.com/hashtag/ayaotd?__eep__=6&__cft__[0]=AZWJWQndS1sZVZGIjtAekJzP9ho_Qo1Dw560Xx5XZsGHpH4aasP5CF7-JDeHCWkQDImnxGhzOrdi8mJJH2q5q8iib5ouVTpyhVw1mq-vGn9nFC5VS1rORrdjaXyIPCjrYikLQknI_jVRnzAOlYaZUrkB2l33YXkFW2x0_R2haLn9igjRokaQ0QlzviJAMBf1DPtFZfayVEbnLU3UEQqliViwMMtwq1wvHM25IbPbYBD4XQ&__tn__=*NK-y-R https://www.facebook.com/hashtag/areyouafraidofthedark?__eep__=6&__cft__[0]=AZWJWQndS1sZVZGIjtAekJzP9ho_Qo1Dw560Xx5XZsGHpH4aasP5CF7-JDeHCWkQDImnxGhzOrdi8mJJH2q5q8iib5ouVTpyhVw1mq-vGn9nFC5VS1rORrdjaXyIPCjrYikLQknI_jVRnzAOlYaZUrkB2l33YXkFW2x0_R2haLn9igjRokaQ0QlzviJAMBf1DPtFZfayVEbnLU3UEQqliViwMMtwq1wvHM25IbPbYBD4XQ&__tn__=*NK-y-R https://www.facebook.com/hashtag/jasonalisharan?__eep__=6&__cft__[0]=AZWJWQndS1sZVZGIjtAekJzP9ho_Qo1Dw560Xx5XZsGHpH4aasP5CF7-JDeHCWkQDImnxGhzOrdi8mJJH2q5q8iib5ouVTpyhVw1mq-vGn9nFC5VS1rORrdjaXyIPCjrYikLQknI_jVRnzAOlYaZUrkB2l33YXkFW2x0_R2haLn9igjRokaQ0QlzviJAMBf1DPtFZfayVEbnLU3UEQqliViwMMtwq1wvHM25IbPbYBD4XQ&__tn__=*NK-y-R https://www.facebook.com/hashtag/nathanielmoreau?__eep__=6&__cft__[0]=AZWJWQndS1sZVZGIjtAekJzP9ho_Qo1Dw560Xx5XZsGHpH4aasP5CF7-JDeHCWkQDImnxGhzOrdi8mJJH2q5q8iib5ouVTpyhVw1mq-vGn9nFC5VS1rORrdjaXyIPCjrYikLQknI_jVRnzAOlYaZUrkB2l33YXkFW2x0_R2haLn9igjRokaQ0QlzviJAMBf1DPtFZfayVEbnLU3UEQqliViwMMtwq1wvHM25IbPbYBD4XQ&__tn__=*NK-y-R https://www.facebook.com/hashtag/rachelblanchard?__eep__=6&__cft__[0]=AZWJWQndS1sZVZGIjtAekJzP9ho_Qo1Dw560Xx5XZsGHpH4aasP5CF7-JDeHCWkQDImnxGhzOrdi8mJJH2q5q8iib5ouVTpyhVw1mq-vGn9nFC5VS1rORrdjaXyIPCjrYikLQknI_jVRnzAOlYaZUrkB2l33YXkFW2x0_R2haLn9igjRokaQ0QlzviJAMBf1DPtFZfayVEbnLU3UEQqliViwMMtwq1wvHM25IbPbYBD4XQ&__tn__=*NK-y-R https://www.facebook.com/hashtag/rosshull?__eep__=6&__cft__[0]=AZWJWQndS1sZVZGIjtAekJzP9ho_Qo1Dw560Xx5XZsGHpH4aasP5CF7-JDeHCWkQDImnxGhzOrdi8mJJH2q5q8iib5ouVTpyhVw1mq-vGn9nFC5VS1rORrdjaXyIPCjrYikLQknI_jVRnzAOlYaZUrkB2l33YXkFW2x0_R2haLn9igjRokaQ0QlzviJAMBf1DPtFZfayVEbnLU3UEQqliViwMMtwq1wvHM25IbPbYBD4XQ&__tn__=*NK-y-Rhttps://www.facebook.com/hashtag/raineparecoull?__eep__=6&__cft__[0]=AZWJWQndS1sZVZGIjtAekJzP9ho_Qo1Dw560Xx5XZsGHpH4aasP5CF7-JDeHCWkQDImnxGhzOrdi8mJJH2q5q8iib5ouVTpyhVw1mq-vGn9nFC5VS1rORrdjaXyIPCjrYikLQknI_jVRnzAOlYaZUrkB2l33YXkFW2x0_R2haLn9igjRokaQ0QlzviJAMBf1DPtFZfayVEbnLU3UEQqliViwMMtwq1wvHM25IbPbYBD4XQ&__tn__=*NK-y-R https://www.facebook.com/hashtag/jodieresther?__eep__=6&__cft__[0]=AZWJWQndS1sZVZGIjtAekJzP9ho_Qo1Dw560Xx5XZsGHpH4aasP5CF7-JDeHCWkQDImnxGhzOrdi8mJJH2q5q8iib5ouVTpyhVw1mq-vGn9nFC5VS1rORrdjaXyIPCjrYikLQknI_jVRnzAOlYaZUrkB2l33YXkFW2x0_R2haLn9igjRokaQ0QlzviJAMBf1DPtFZfayVEbnLU3UEQqliViwMMtwq1wvHM25IbPbYBD4XQ&__tn__=*NK-y-R https://www.facebook.com/hashtag/jacobtierney?__eep__=6&__cft__[0]=AZWJWQndS1sZVZGIjtAekJzP9ho_Qo1Dw560Xx5XZsGHpH4aasP5CF7-JDeHCWkQDImnxGhzOrdi8mJJH2q5q8iib5ouVTpyhVw1mq-vGn9nFC5VS1rORrdjaXyIPCjrYikLQknI_jVRnzAOlYaZUrkB2l33YXkFW2x0_R2haLn9igjRokaQ0QlzviJAMBf1DPtFZfayVEbnLU3UEQqliViwMMtwq1wvHM25IbPbYBD4XQ&__tn__=*NK-y-R https://www.facebook.com/hashtag/djmachale?__eep__=6&__cft__[0]=AZWJWQndS1sZVZGIjtAekJzP9ho_Qo1Dw560Xx5XZsGHpH4aasP5CF7-JDeHCWkQDImnxGhzOrdi8mJJH2q5q8iib5ouVTpyhVw1mq-vGn9nFC5VS1rORrdjaXyIPCjrYikLQknI_jVRnzAOlYaZUrkB2l33YXkFW2x0_R2haLn9igjRokaQ0QlzviJAMBf1DPtFZfayVEbnLU3UEQqliViwMMtwq1wvHM25IbPbYBD4XQ&__tn__=*NK-y-R https://www.facebook.com/hashtag/nedkandel?__eep__=6&__cft__[0]=AZWJWQndS1sZVZGIjtAekJzP9ho_Qo1Dw560Xx5XZsGHpH4aasP5CF7-JDeHCWkQDImnxGhzOrdi8mJJH2q5q8iib5ouVTpyhVw1mq-vGn9nFC5VS1rORrdjaXyIPCjrYikLQknI_jVRnzAOlYaZUrkB2l33YXkFW2x0_R2haLn9igjRokaQ0QlzviJAMBf1DPtFZfayVEbnLU3UEQqliViwMMtwq1wvHM25IbPbYBD4XQ&__tn__=*NK-y-R https://www.facebook.com/hashtag/cinar?__eep__=6&__cft__[0]=AZWJWQndS1sZVZGIjtAekJzP9ho_Qo1Dw560Xx5XZsGHpH4aasP5CF7-JDeHCWkQDImnxGhzOrdi8mJJH2q5q8iib5ouVTpyhVw1mq-vGn9nFC5VS1rORrdjaXyIPCjrYikLQknI_jVRnzAOlYaZUrkB2l33YXkFW2x0_R2haLn9igjRokaQ0QlzviJAMBf1DPtFZfayVEbnLU3UEQqliViwMMtwq1wvHM25IbPbYBD4XQ&__tn__=*NK-y-R https://www.facebook.com/hashtag/nickelodeon?__eep__=6&__cft__[0]=AZWJWQndS1sZVZGIjtAekJzP9ho_Qo1Dw560Xx5XZsGHpH4aasP5CF7-JDeHCWkQDImnxGhzOrdi8mJJH2q5q8iib5ouVTpyhVw1mq-vGn9nFC5VS1rORrdjaXyIPCjrYikLQknI_jVRnzAOlYaZUrkB2l33YXkFW2x0_R2haLn9igjRokaQ0QlzviJAMBf1DPtFZfayVEbnLU3UEQqliViwMMtwq1wvHM25IbPbYBD4XQ&__tn__=*NK-y-RCheck out:http://talesfromthepodcast.com/?fbclid=IwZXh0bgNhZW0CMTAAAR2LzjyUorHBG-ciSs1VjctfWaKDHrtX0IglZwQ4dkRcCJkx5rMVS1q6nIM_aem_htosP9CGs7UABQLYFzRuQwhttp://linktr.ee/skewereduniversepodcast?fbclid=IwZXh0bgNhZW0CMTAAAR3_xS9vb_OW45774n6SOPNlds8imbVlldm9TmBThZcOvNppxNPBfXj9GRU_aem_mq8YZWyniiGEnsl70p8jOAhttp://happyhournewsteam.com/?fbclid=IwZXh0bgNhZW0CMTAAAR2LzjyUorHBG-ciSs1VjctfWaKDHrtX0IglZwQ4dkRcCJkx5rMVS1q6nIM_aem_htosP9CGs7UABQLYFzRuQwAnd can contact me through email here at talesfromthepodcast13@gmail.WooHoo!!!Tales From The Podcast The Fucking Video Game out now for PC!Purchase now for $10Send payment and email to:PayPal - talesfromthepodcast13@gmail.comCashApp - $talesfromthepodcast$5 more and you pansies get a cheatbot!https://www.facebook.com/hashtag/horror?__eep__=6&__cft__[0]=AZWJWQndS1sZVZGIjtAekJzP9ho_Qo1Dw560Xx5XZsGHpH4aasP5CF7-JDeHCWkQDImnxGhzOrdi8mJJH2q5q8iib5ouVTpyhVw1mq-vGn9nFC5VS1rORrdjaXyIPCjrYikLQknI_jVRnzAOlYaZUrkB2l33YXkFW2x0_R2haLn9igjRokaQ0QlzviJAMBf1DPtFZfayVEbnLU3UEQqliViwMMtwq1wvHM25IbPbYBD4XQ&__tn__=*NK-y-R https://www.facebook.com/hashtag/rpg?__eep__=6&__cft__[0]=AZWJWQndS1sZVZGIjtAekJzP9ho_Qo1Dw560Xx5XZsGHpH4aasP5CF7-JDeHCWkQDImnxGhzOrdi8mJJH2q5q8iib5ouVTpyhVw1mq-vGn9nFC5VS1rORrdjaXyIPCjrYikLQknI_jVRnzAOlYaZUrkB2l33YXkFW2x0_R2haLn9igjRokaQ0QlzviJAMBf1DPtFZfayVEbnLU3UEQqliViwMMtwq1wvHM25IbPbYBD4XQ&__tn__=*NK-y-R https://www.facebook.com/hashtag/indiegame?__eep__=6&__cft__[0]=AZWJWQndS1sZVZGIjtAekJzP9ho_Qo1Dw560Xx5XZsGHpH4aasP5CF7-JDeHCWkQDImnxGhzOrdi8mJJH2q5q8iib5ouVTpyhVw1mq-vGn9nFC5VS1rORrdjaXyIPCjrYikLQknI_jVRnzAOlYaZUrkB2l33YXkFW2x0_R2haLn9igjRokaQ0QlzviJAMBf1DPtFZfayVEbnLU3UEQqliViwMMtwq1wvHM25IbPbYBD4XQ&__tn__=*NK-y-R https://www.facebook.com/hashtag/pcgaming?__eep__=6&__cft__[0]=AZWJWQndS1sZVZGIjtAekJzP9ho_Qo1Dw560Xx5XZsGHpH4aasP5CF7-JDeHCWkQDImnxGhzOrdi8mJJH2q5q8iib5ouVTpyhVw1mq-vGn9nFC5VS1rORrdjaXyIPCjrYikLQknI_jVRnzAOlYaZUrkB2l33YXkFW2x0_R2haLn9igjRokaQ0QlzviJAMBf1DPtFZfayVEbnLU3UEQqliViwMMtwq1wvHM25IbPbYBD4XQ&__tn__=*NK-y-R https://www.facebook.com/hashtag/oldschool?__eep__=6&__cft__[0]=AZWJWQndS1sZVZGIjtAekJzP9ho_Qo1Dw560Xx5XZsGHpH4aasP5CF7-JDeHCWkQDImnxGhzOrdi8mJJH2q5q8iib5ouVTpyhVw1mq-vGn9nFC5VS1rORrdjaXyIPCjrYikLQknI_jVRnzAOlYaZUrkB2l33YXkFW2x0_R2haLn9igjRokaQ0QlzviJAMBf1DPtFZfayVEbnLU3UEQqliViwMMtwq1wvHM25IbPbYBD4XQ&__tn__=*NK-y-R https://www.facebook.com/hashtag/funny?__eep__=6&__cft__[0]=AZWJWQndS1sZVZGIjtAekJzP9ho_Qo1Dw560Xx5XZsGHpH4aasP5CF7-JDeHCWkQDImnxGhzOrdi8mJJH2q5q8iib5ouVTpyhVw1mq-vGn9nFC5VS1rORrdjaXyIPCjrYikLQknI_jVRnzAOlYaZUrkB2l33YXkFW2x0_R2haLn9igjRokaQ0QlzviJAMBf1DPtFZfayVEbnLU3UEQqliViwMMtwq1wvHM25IbPbYBD4XQ&__tn__=*NK-y-R https://www.facebook.com/hashtag/adult?__eep__=6&__cft__[0]=AZWJWQndS1sZVZGIjtAekJzP9ho_Qo1Dw560Xx5XZsGHpH4aasP5CF7-JDeHCWkQDImnxGhzOrdi8mJJH2q5q8iib5ouVTpyhVw1mq-vGn9nFC5VS1rORrdjaXyIPCjrYikLQknI_jVRnzAOlYaZUrkB2l33YXkFW2x0_R2haLn9igjRokaQ0QlzviJAMBf1DPtFZfayVEbnLU3UEQqliViwMMtwq1wvHM25IbPbYBD4XQ&__tn__=*NK-y-R https://www.facebook.com/hashtag/sexy?__eep__=6&__cft__[0]=AZWJWQndS1sZVZGIjtAekJzP9ho_Qo1Dw560Xx5XZsGHpH4aasP5CF7-JDeHCWkQDImnxGhzOrdi8mJJH2q5q8iib5ouVTpyhVw1mq-vGn9nFC5VS1rORrdjaXyIPCjrYikLQknI_jVRnzAOlYaZUrkB2l33YXkFW2x0_R2haLn9igjRokaQ0QlzviJAMBf1DPtFZfayVEbnLU3UEQqliViwMMtwq1wvHM25IbPbYBD4XQ&__tn__=*NK-y-R

In today's episode, we discuss the process of registering a company for government contracts. The very first step is to analyze the company and help them obtain necessary codes, such as a CAGE code and an NK code, to register in the System for Award Management (SAM). However, if the company is not based in the Middle East, they only need an NK code and SAM registration. It's important to analyze the company beforehand to ensure you are eligible and qualified for jobs and opportunities. Listen to this episode if you want to know more!

Your body contains trillions of cells, and the secret to reversing aging, healing chronic illness, and fighting inflammation lies in how they communicate. Join Dr. Josh Axe as he interviews Dr. Rafael Gonzalez, one of the world's leading experts in regenerative medicine, to uncover the science behind stem cells, NK cells, and exosomes and how they could transform your health. Dr. Gonzalez shares groundbreaking insights into the latest advancements in regenerative therapies, drawing from his 17+ years of research and clinical practice. As a survivor of a life-changing spinal infection, Dr. Axe explains how stem cell therapy played a key role in his recovery. You'll learn: Why not all stem cells are created equal and how to ensure you're getting the best quality How stem cells can reverse autoimmune disease, chronic pain, and even autism symptoms What "zombie cells" are and how they accelerate aging and chronic illness The science behind NK (natural killer) cells and how they fight cancer, viruses, and senescence How stem cells help your body regenerate tissue, increase blood flow, and reduce inflammation The difference between stem cells, exosomes, and NK cells—and when to use each therapy Why nutrition, lifestyle, and cellular health play a critical role in the success of these therapies Tune in now to discover how regenerative medicine could be the key to unlocking better health, reversing aging, and healing from chronic disease. You'll walk away with actionable insights and an understanding of how to access these life-changing therapies. #stemcelltherapy #regenerativemedicine #antiaging Want more of The Dr. Josh Axe Show? Subscribe to the YouTube channel. Follow Dr. Josh Axe Instagram Twitter Facebook TikTok Website Follow Rafael Gonzalez Instagram ------  Staying healthy in today's world is an upstream battle. Subscribe to Wellness Weekly, your 5-minute dose of sound health advice to help you grow physically, mentally, and spiritually. Every Wednesday, you'll get: Holistic health news & life-hacks from a biblical world view Powerful free resources including classes, Q&As, and guides from Dr. Axe The latest episodes of The Dr. Josh Axe Show Sign up here → https://forms.thehealthinstitute.com/l-77  Submit your questions via voice memo to be featured on the show → speakpipe.com/drjoshaxe  ------  Links: Join keynote Dr. Josh Axe and other keynote speakers for an unforgettable weekend at Rehealth's 1st Annual, Biohack Your Cells Conference in Los Cabos, Mexico. Register and save 10% with code “AXE”!